Rodman & Renshaw Annual Global Investment Conference Presenter Profiles
NEW YORK--(BUSINESS WIRE)-- The Rodman & Renshaw Annual Global Investment Conference takes place Sept. 09 - 11, 2009 at the New York Palace Hotel in New York City.
Business Wire is the official news wire for the Rodman & Renshaw Annual Global Investment Conference. The conference is comprised of the Annual Healthcare Conference and 7 other industry tracks:
Rodman & Renshaw 11th Annual Healthcare Conference
Rodman & Renshaw Metals & Mining Track
Rodman & Renshaw Energy Track
Rodman & Renshaw Cleantech Track
Rodman & Renshaw Asia Track
Rodman & Renshaw Maritime Track
Rodman & Renshaw Community & Regional Bank Track
Rodman & Renshaw Growth Track
Breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource.
Listed below are Rodman & Renshaw Annual Global Investment Conference presenter profiles.
Company: | Â | Active Biotech AB | |
Ticker Symbol & Exchange: | ACTI (SEK) | ||
Investor Relations Contact: | Mr. Göran Forsberg, VP IR & BD | ||
Investor Relations Contact Phone: | 46 46 19 11 54 | ||
Web: | www.activebiotech.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDexâ„¢ for RA. | |||
 | |||
 | |||
Company: | Acucela Inc. | ||
Investor Relations Contact: | Jennifer Beugelmans | ||
Investor Relations Contact Phone: | (646) 596-7473 | ||
Web: | www.Acucela.com | ||
Date of Presentation: | Wednesday, September 9, 2009 | ||
 | |||
Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The company’s orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela, with partner Otsuka Pharmaceutical, is also developing Rebamipide ophthalmic suspension, its Phase 3 program for dry eye. For more information, please visit www.Acucela.com. | |||
 | |||
 | |||
Company: | Advanced Life Sciences | ||
Ticker Symbol & Exchange: | ADLS OTC:BB | ||
Investor Relations Contact: | Joe Camp | ||
Investor Relations Contact Phone: | 630-754-4352 | ||
Web: | www.advancedlifesciences.com | ||
Date of Presentation: | Thursday, September 10 9:35 AM EDT | ||
 | |||
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer, respiratory diseases and biodefense. For more information, please visit us on the web at www.advancedlifesciences.com. | |||
 | |||
The company will presenting in the Hubbard Salon at The New York Palace Hotel at 455 Madison Avenue in New York City. A live and archived webcast of the call will be available at the company's website. | |||
 | |||
 | |||
Company: | Advent Energy Ltd | ||
Investor Relations Contact: | David Breeze | ||
Investor Relations Contact Phone: | 61 8 9328 8711, 0409 150 953 | ||
Web: | www.adventenergy.com.au | ||
Date of Presentation: | Friday 11 September, 2009 at 2.50pm | ||
 | |||
Advent Energy Ltd is an unlisted Oil and Gas exploration company with a strong asset portfolio containing near term production opportunities and exploration upside. Advent is pursuing its option to earn 85% in cornerstone project PEP 11 – offshore Sydney Basin. | |||
 | |||
The Sydney Basin is a proven petroleum basin with excellent potential for the discovery of gas and oil. The recent demonstration of an active hydrocarbon system with seeps reported in the offshore area confirmed the presence of thermogenic hydrocarbon gas; this is considered to occur in basins actively generating hydrocarbons and /or that contain excellent migration pathways. | |||
 | |||
 | |||
Company: | Allon Therapeutics Inc. | ||
Ticker Symbol & Exchange: | TSX:NPC | ||
Investor Relations Contact: | Aaron Keay | ||
Investor Relations Contact Phone: | (604) 323-6911 | ||
Web: | www.allontherapeutics.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon’s drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease, and schizophrenia-related cognitive impairment. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer’s disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol “NPC†(Neuro Protection CompanyTM) and based in Vancouver. For additional information please visit the Company’s website: www.allontherapeutics.com. | |||
 | |||
 | |||
Company: | AllTranz Inc. | ||
Investor Relations Contact: | Clint Dederick | ||
Investor Relations Contact Phone: | 513-252-7894 | ||
Web: | www.alltranz.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
AllTranz Inc. is a specialty pharmaceutical company based in Lexington, KY. AllTranz will be a leader in the advancement of pain therapy by developing innovative prodrug strategies delivered via unique dermal delivery solutions to treat a variety of pain disorders. AllTranz leverages proprietary technology to modify existing chemical entities with proven clinical outcomes to produce important new pharmaceutical products that extend patent franchises. The Company’s expertise in formulation, prodrug development, and dermal delivery products exploits the opportunity for lower risk development pathways to significant new drugs. We are currently looking to close on strategic alliances and a Series B round. | |||
 | |||
 | |||
Company: | Altairnano, Inc. | ||
Ticker Symbol & Exchange: | ALTI | ||
Investor Relations Contact: | Todd Carney | ||
Investor Relations Contact Phone: | 775-858-3727 | ||
Web: | www.altairnano.com | ||
Date of Presentation: | September 9, 2009; 9:25am | ||
 | |||
Headquartered in Reno, NV, Altairnano is a leading provider of energy storage systems for clean, efficient power and energy management. Designed for power-dependent applications, Altairnano’s advanced lithium-ion energy storage systems and batteries are responding to changing demands in energy generation, utilization, and policy. Whether it’s reducing dependencies on traditional generation facilities, reducing carbon emissions, or accelerating the adoption of renewable integration and alternative-fuel vehicles, Altairnano helps achieve sustainable, and economically sensible, power and energy management practices. | |||
 | |||
With proprietary technologies, proven market acceptance, and production scalability, Altairnano is uniquely positioned to help solve the challenges and opportunities of an energy-focused economy. | |||
 | |||
 | |||
Company: | Altea Therapeutics | ||
Investor Relations Contact: | Angela Walsh | ||
Investor Relations Contact Phone: | 404-835-6430 | ||
Web: | www.alteatherapeutics.com | ||
Date of Presentation: | 9/11/09 at 2p | ||
 | |||
Altea Therapeutics is a clinical-stage pharmaceutical company with a proprietary platform technology applicable to transdermal delivery of biologicals and water soluble drugs that are typically administered by needle injection or infusion. Altea Therapeutics is developing and commercializing initial products with pharmaceutical industry, including two products with Amylin/Lilly (exenatide) and Hospira (undisclosed). Altea Therapeutics is also developing transdermal patches delivering basal insulin, PTH and fentanyl citrate that are available for partnering. Altea Therapeutics is undertaking several collaborations with pharmaceutical companies to assess the feasibility of transdermal delivery of their drugs, each with potential to become a full development and commercialization partnership. | |||
 | |||
 | |||
Company: | American Lorain Corporation | ||
Ticker Symbol & Exchange: | OTC BB: ALRC | ||
Investor Relations Contact: | Alan Jin, CFO | ||
Investor Relations Contact Phone: | Crocker Coulson, CCG, 1(646) 213-1915 | ||
Web: | www.americanlorain.com | ||
Date of Presentation: | 10:25AM on Wed. Sept. 9, 2009 | ||
 | |||
American Lorain Corporation, (“American Lorainâ€, the “Companyâ€) is a leading processed foods company operating in China through its four direct and indirect subsidiaries and one leased factory. The Company produces and sells chestnuts, convenience foods, and frozen, canned, and bulk food prodcucts to both domestic and international customers. The Company’s current product portfolio includes 234 products and sales channels reach 26 provinces and administrative regions in China as well as 42 foreign countries. | |||
 | |||
 | |||
Company: | [ANTARES PHARMA INC.] | ||
Ticker Symbol & Exchange: | (NYSE AMEX: AIS) | ||
Investor Relations Contact: | Lisa Wilson | ||
Investor Relations Contact Phone: | (917) 543-9932 | ||
Web: | www.antarespharma.com | ||
Date of Presentation: | Thursday, September 10th | ||
 | |||
Antares Pharma is a revenue-generating, product-focused company that has developed proprietary drug-delivery platforms, two of which now include FDA-approved products. Our products improve safety and efficacy profiles by minimizing dosing and reducing side effects. | |||
 | |||
Antares was formed in 2001 when Medi-Ject Corporation (a device company) merged with Permatec Holding AG (developer of ATDâ„¢ gel transdermal delivery systems). Presently we have broad approval for our needle-free device in the US for insulin and in Europe, Asia and the US for human growth hormone. In addition, we have a disposable pressure assisted auto injector product which uses a disposable single use small gauge needle for unit dose injectable drugs; we have recently added a disposable multi-use pen injector. | |||
 | |||
 | |||
Company: | Antisoma | ||
Ticker Symbol & Exchange: | LSE: ASM; USOTC: ATS | ||
Investor Relations Contact: | Dr Daniel Elger | ||
Investor Relations Contact Phone: | 44 7909 915 068 | ||
Web: | www.antisoma.com | ||
Date of Presentation: | September 10th, | ||
 | |||
Based in London, UK, and Cambridge, MA, Antisoma is focused on the development and commercialization of new treatments for cancer. Antisoma has a worldwide development and marketing partnership with Novartis for ASA404, a potential blockbuster Tumor-Vascular Disrupting Agent in phase III development for lung cancer. Antisoma retains marketing rights to its other pipeline products, including a further phase III drug, AS1413, which is in a pivotal phase III trial for secondary AML. The Company intends to sell these products itself in the US whilst seeking partnerships for marketing in other territories. Please visit www.Antisoma.com for further information about Antisoma. | |||
 | |||
 | |||
Company: | Arena Resources, Inc. | ||
Ticker Symbol & Exchange: | ARD NYSE | ||
Investor Relations Contact: | Bill Parsons | ||
Investor Relations Contact Phone: | (480) 947-1589 | ||
Web: | www.arenaresourcesinc.com | ||
Date of Presentation: | 09/09/09 | Â | |
Arena Resources, Inc. (NYSE: ARD) is an Oklahoma-based oil and gas exploration, development and production company with current operations in Texas, Oklahoma, Kansas and New Mexico. Founded in 2000, the experienced management team has aggressively sought to acquire select properties in their “back yard†which provides immediate positive cash flow and development opportunities for future years. As of December 31, 2008, the company has an estimated 65.6 million BOE’s (barrel of oil equivalents) and an estimated $651.6 million* in PV-10 (future net revenues discounted 10%). | |||
 | |||
*Independent audit prepared 12/31/08 using $38.30 per barrel of oil / $4.35 per mcf of natural gas. | |||
 | |||
 | |||
Company: | ARIAD Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | NASDAQ: ARIA | ||
Investor Relations Contact: | Maria E. Cantor | ||
Investor Relations Contact Phone: | 617-621-2208 | ||
Web: | www.ariad.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD’s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD’s second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers, including CML. | |||
 | |||
 | |||
Company: | AspenBio Pharma, Inc. | ||
Ticker Symbol & Exchange: | APPY | ||
Investor Relations Contact: | Ron Liolios Group | ||
Investor Relations Contact Phone: | 949-574-3860 | ||
Web: | www.aspenbiopharma.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
AspenBio Pharma is an emerging biotechnology company dedicated to the discovery, development and commercialization of novel products that address unmet diagnostic and therapeutic needs in both human and animal health. | |||
 | |||
The company’s AppyScore blood-based test addresses the difficult challenge of diagnosing human appendicitis in the hospital emergency department. The company is also advancing unique therapeutic proteins designed to improve reproduction in non-companion animals of economic importance. | |||
 | |||
 | |||
Company: | Austral Gold Limited | ||
Ticker Symbol & Exchange: | AGD | ||
Investor Relations Contact: | Mark Bethwaite | ||
Investor Relations Contact Phone: | 61 4199 34860 | ||
Web: | www.australgold.com.au | ||
Date of Presentation: | Friday 11 September, 2009 | ||
 | |||
Austral Gold Limited (ASX AGD) is an Australian-based exploration junior. The company is advancing its 100%-owned Guanaco gold, copper and silver project in Chile, where it is reviewing a Feasibility Study to restart mining operations. | |||
 | |||
Guanaco is located 220 kilometres southeast of Antofagasta and gold has been mined in the area since 1886. Following Austral Gold’s successful drill campaign in 2008, total resources have been increased to 904,361oz of gold and 3,930,309oz of silver. | |||
 | |||
Austral Gold has exploration prospects in Australia and in Argentina, in addition to its flagship project in Chile. | |||
 | |||
 | |||
Company: | Avalon Rare Metals Inc. | ||
Ticker Symbol & Exchange: | TSX:AVL, OTCQX:AVARF | ||
Investor Relations Contact: | Don Bubar / Virginia Morgan | ||
Investor Relations Contact Phone: | 416-364-4938 | ||
Web: | www.avalonraremetals.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Avalon Rare Metals Inc. (TSX:AVL, OTCQX:AVARF) is a mineral exploration and development company focused on rare metals deposits in Canada. Its flagship project, 100%-owned Lake Zone Deposit, Thor Lake, NWT, is emerging as one of the largest undeveloped rare earth elements (“REEâ€) resources in the world. Its exceptional enrichment in the more valuable ‘heavy’ REE, which are key to enabling advances in green energy technology and other growing high-tech applications, is one of the few potential sources of these critical elements outside of China, currently the source of 95% of world supply. Social responsibility and environmental stewardship are corporate cornerstones. | |||
 | |||
 | |||
Company: | Avanir Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | AVNR / NASDAQ | ||
Investor Relations Contact: | Eric Benevich or Brenna Mullen | ||
Investor Relations Contact Phone: | (949)389-6700 | ||
Web: | www.avanir.com | ||
Date of Presentation: | September 10, 2009 at 10:50am ET | ||
 | |||
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. Avanir’s lead product candidate, Zenvia™, is in Phase III development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic (DPN) pain. | |||
 | |||
Recently, Avanir announced positive results from the confirmatory Phase III STAR trial where both doses of Zenvia demonstrated a significant reduction of PBA episode rates compared to placebo. The Company plans to submit a complete response to the PBA approvable letter and anticipates an FDA approval decision in the second half of 2010. | |||
 | |||
 | |||
Company: | AXION POWER INTERNATIONAL INC | ||
Ticker Symbol & Exchange: | OTC BB: AXPW | ||
Investor Relations Contact: | Rudy Barrio | ||
Investor Relations Contact Phone: | 212.691.8087 | ||
Web: | www.axionpower.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Axion’s principal, potentially disruptive technology is its PbC® battery, developed to play an important role in the burgeoning electric, micro- and mild-hybrid car markets, defense applications, utility and industrial energy storage, renewable energy (wind, solar), grid-related (uninterruptible power, load-leveling, peak shaving) and other emerging markets. Among the advantages of Axion’s new PbC® technology, which won a Frost and Sullivan Innovation Award for North America, are efficiency, sustainability, manufacturability and ease of recycling. PbC technology uses nanoporous activated carbon electrode assemblies to replace the simple lead-based negative electrodes used by other lead-acid battery manufacturers. | |||
 | |||
Axion is working with Exide Technologies, one of the world’s largest producers and recyclers of lead-acid batteries. | |||
 | |||
 | |||
Company: | AZURE DYNAMICS | ||
Ticker Symbol & Exchange: | OTCQX:AZDDF | ||
Investor Relations Contact: | Michael Mason | ||
Investor Relations Contact Phone: | 212.691.8087 | ||
Web: | www.azuredynamics.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Azure Dynamics is a leading innovator in the development of environmentally friendly and cost effective hybrid electric and electric technologies for commercial vehicles. | |||
 | |||
The Company supplies hybrid electric vehicle (HEV) and electric vehicle (EV) control and powertrain systems for delivery fleets, utility vehicles, and shuttle buses. Azure has an established portfolio of proprietary component products that compliments its core technical skills and makes use of an extensive supplier base to offer complete powertrain solutions to its target market. | |||
 | |||
Azure has partnered with seven of the leading bus body manufacturers in the US and Canada and with 27 Ford commercial truck dealerships in key markets across North America. These partnerships give Azure significant market presence and expanded sales and service capabilities. | |||
 | |||
 | |||
Company: | B.O.S. Better Online Solutions Ltd. | ||
Ticker Symbol & Exchange: | Nasdaq:BOSC | ||
Investor Relations Contact: | Zipi Weinreich, [email protected] | ||
Investor Relations Contact Phone: | 972-3-9541008 | ||
Web: | www.boscom.com | ||
 | |||
B.O.S. Better Online Solutions Ltd (Nasdaq:BOSC) is a leading provider of RFID, Mobile and Supply Chain solutions to global enterprises. BOS' proprietary BOSERVER, BOSaNova, RFID, Mobile and supply chain offerings are being used to improve the efficiency of enterprise logistics and organizational monitoring and control systems of over 2000 customers worldwide. With BOS solutions, companies are enhancing the automation of various aspects of their supply chain, improving asset tracking, and managing real-time business data, all crucial to improving margins in today's competitive marketplace. | |||
 | |||
 | |||
Company: | BELLUS Health Inc. | ||
Ticker Symbol & Exchange: | TSX: BLU | ||
Investor Relations Contact: | Michelle Stein | ||
Investor Relations Contact Phone: | 450 680 4573 | ||
Web: | www.bellushealth.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs. The Company’s pharmaceutical strategy includes the development of investigational product candidates for the treatment of Amyloid A amyloidosis, Type II diabetes and certain features of metabolic syndrome, and Alzheimer’s disease. BELLUS Health's pipeline contains promising therapeutic products at various stages of development that have the potential to be large growth drivers. BELLUS Health's wholly owned subsidiary, OVOS Natural Health, is expected to generate revenue and profit through the marketing of branded nutraceutical products. | |||
 | |||
 | |||
Company: | Bio-Bridge Science, Inc. | ||
Ticker Symbol & Exchange: | OTCBB: BGES | ||
Investor Relations Contact: | Chris Young | ||
Investor Relations Contact Phone: | 630-928-0869 | ||
Web: | www.bio-bridge-science.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Bio-Bridge Science, a biotechnology company, focuses on the commercial development of biological products for the prevention and treatment of human diseases, and production materials in producing vaccines. Its products under development include an HIV vaccine, a vaccine to prevent AIDS; a colon cancer therapeutic vaccine; and an HPV vaccine to prevent cervical cancer. It holds license for the HIV and colon cancer vaccine technology in China, Japan, and the US. It also sells bovine serum, a vaccine production material, and expects to form a joint venture to produce cell culture medium, another vaccine production material, in the near future. |
|||
 | |||
 | |||
Company: | BioSante Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | BPAX: NASDAQ | ||
Investor Relations Contact: | Phillip Donenberg | ||
Investor Relations Contact Phone: | 847-478-0500 ext 100 | ||
Web: | www.biosantepharma.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II/III clinical development. | |||
 | |||
 | |||
Company: | Biotie Therapies Corp. | ||
Ticker Symbol & Exchange: | BTHIV NASDAQ OMX | ||
Investor Relations Contact: | Dr Thomas Taapken | ||
Investor Relations Contact Phone: | 358 2 274 8900 | ||
Web: | www.biotie.com | ||
Date of Presentation: | Wednesday September 9, 2009 | ||
 | |||
Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. | |||
 | |||
The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Wyeth. | |||
 | |||
 | |||
Company: | Blaze Energy Ltd. | ||
Investor Relations Contact: | Kevin Donegan | ||
Investor Relations Contact Phone: | 403-264-0877 ext. 814 | ||
Web: | www.blazeenergy.com | ||
Date of Presentation: | September 9, 2009 4:55PM | ||
 | |||
Blaze Energy Ltd., formed in 1995, is an entrepreneurial Canadian private oil and natural gas exploration and development company with midstream operations. Blaze is producing 650 BOE/d from its core assets in West Central Alberta, Canada, and unlike many of its junior peers, it owns, operates and processes third party natural gas through its 185 mmcf/d plant located in Brazeau, Alberta. Blaze is adding value through: | |||
 | |||
i) continuing to drill its prolific, multi-zone, low-density, liquids rich core area with exploration upside; | |||
 | |||
ii) evaluating the resource potential of its core area as competitors continue to make horizontal drilling announcements; | |||
 | |||
iii) increasing third party natural gas processing; | |||
 | |||
iv) technical feasibility established, commercial feasibility under review of natural gas storage and enhanced oil recovery scheme. | |||
 | |||
 | |||
Company: | Boots & Coots, Inc. | ||
Ticker Symbol & Exchange: | NYSE Amex: WEL | ||
Investor Relations Contact: | Jennifer Tweeton | ||
Investor Relations Contact Phone: | 281-931-8884 | ||
Web: | www.boots-coots.com | ||
Date of Presentation: | 09/09/09, 2:50 PM | ||
 | |||
Boots & Coots provides a suite of integrated pressure control services to oil and gas companies around the world. Boots & Coots’ services include well intervention services designed to enhance oil and gas productions. These services consist primarily of hydraulic workover and snubbing services. Boots & Coots’ equipment services segment provides high pressure, high temperature rental tools. The company’s pressure control services are designed to reduce the number and severity of critical events such as well fires, blowouts or other incidences due to loss of control at the well. This segment includes the company’s Safeguard prevention and emergency response services. | |||
 | |||
 | |||
Company: | Bow Energy Limited | ||
Ticker Symbol & Exchange: | BOW:ASX | ||
Investor Relations Contact: | John De Stefani | ||
Investor Relations Contact Phone: | (617) 3303 0675 | ||
Web: | www.bowenergy.com.au | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Bow Energy Limited is a leading energy company based in Brisbane, Australia. It has a highly prospective portfolio of coal seam gas (CSG) acreage in Queensland’s Bowen and Surat Basins, strategically located adjacent to established CSG projects and near the planned Gladstone liquefied natural gas projects. Bow has over 660 PJ of 3P certifed gas reserves. Bow also has conventional oil projects in the Cooper, Eromanga and Surat-Bowen Basins. Bow is listed on the Australian Securities Exchange under the ticker code of BOW, with market capitalization of approximately AUD$280 million (as of August 17, 2009). Refer to www.bowenergy.com.au. | |||
 | |||
 | |||
Company: | BTU International, Inc | ||
Ticker Symbol & Exchange: | BTUI - NASDAQ | ||
Investor Relations Contact: | Bill Monigle | ||
Investor Relations Contact Phone: | 941-497-1622 | ||
Web: | www.btu.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
BTU International is a market-leading, global supplier of advanced thermal processing equipment and processes to the alternative energy and electronics assembly markets. BTU equipment and know-how are used in solar cell, nuclear fuel and fuel cell manufacturing as well as in the production of printed circuit board assemblies and semiconductor packaging. Providers of alternative energy solutions appreciate BTU’s highly efficient products enabling lower cost per watt solutions, whereas semiconductor and electronics manufacturers look for BTU’s high throughput, high yield manufacturing tools and technologies that help them remain competitive. BTU has operations in Massachusetts, USA and Shanghai, China with direct sales and service worldwide. | |||
 | |||
 | |||
Company: | Cangene Corporation | ||
Ticker Symbol & Exchange: | CNJ on TSX | ||
Investor Relations Contact: | Ms. Jean Compton | ||
Investor Relations Contact Phone: | 416-675-8280 | ||
Web: | www.cangene.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Cangene is a profitable and fully integrated developer and manufacturer of immune therapeutics and recombinant biopharmaceuticals, primarily targeting infectious disease and biodefence applications. Most of Cangene’s products are hyperimmunes—purified antibody products that are specific for targets such as hepatitis B, botulism, and anthrax. With nearly 30 years of experience making its lead drug, WinRho® SDF, manufacturing capability is one of Cangene’s key strengths. The Company has operations in Manitoba and Ontario in Canada, and California, Maryland and Florida in the U.S. Most of its 700 employees work in Winnipeg or at its Baltimore subsidiary, Chesapeake Biological Laboratories, Inc. | |||
 | |||
 | |||
Company: | Celladon Corporation | ||
Investor Relations Contact: | Rebecque Laba | ||
Investor Relations Contact Phone: | 858-366-4288 | ||
Web: | www.celladon.net | ||
Date of Presentation: | Friday, September 11th at 2:25p | ||
 | |||
Celladon is a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. Our products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Our first product candidate, MYDICAR®, delivers the gene for the SERCA2a enzyme and is currently being tested in Phase 1 and 2 clinical trials. We are also developing small molecule activators of SERCA2a for acute heart failure. | |||
 | |||
 | |||
Company: | Chariot Resources Limited | ||
Ticker Symbol & Exchange: | CHD:TSX | ||
Investor Relations Contact: | Forbes West | ||
Investor Relations Contact Phone: | 416-203-2200/[email protected] | ||
Web: | www.chariotresources.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Chariot Resources (CHD:TSX) is developing its 70% owned Mina Justa deposit in Peru, one of South America’s premier new copper projects. During the 11.5 year mine life, vat leaching will produce 1.06 billion pounds of cathode copper, and the concentrator will produce concentrates containing 1.32 billion pounds of payable copper, and 16.0 million ounces of payable silver.The Environmental and Social Impact Assessment is scheduled to be submitted to regulators in August. Permitting processes will run in parallel, so approval of the ESIA is followed closely by the granting of permits to make the robust Mina Justa Project “shovel readyâ€. | |||
 | |||
 | |||
Company: | China Advanced Construction Materials | ||
Ticker Symbol & Exchange: | CADC: OTCBB | ||
Investor Relations Contact: | David Waldman | ||
Investor Relations Contact Phone: | 212-671-1020 | ||
Web: | www.china-acm.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
China ACM, founded in 2002 and based in Beijing, China, is a leading producer of advanced construction materials for large scale commercial, residential, and infrastructure developments. The company is primarily focused on producing and supplying a wide range of advanced ready-mix concrete materials for highly technical, large scale, and environmental construction projects. The company also aims to develop and produce new and innovative environmentally conscious construction materials. | |||
 | |||
China ACM provides materials and services through its seven ready-mix concrete plant network covering Beijing metropolitan area. China ACM owns one plant, leases two plants and has technical services and preferred procurement agreements with four other independently-owned plants. | |||
 | |||
 | |||
Company: | China Auto Logicstics Inc. | ||
Ticker Symbol & Exchange: | CALI Nasdaq | ||
Investor Relations Contact: | Ken Donenfeld | ||
Investor Relations Contact Phone: | (212) 425-5700 | ||
Web: | www.chinaautologisticsinc.com/ | ||
Date of Presentation: | Sep 10, 2009 from 3:40 - 4:05 PM | ||
 | |||
China Auto Logistics Inc. is one of China’s top importers of luxury cars and the developer of leading websites for buyers and sellers of imported and domestic automobiles. The Company is also China’s leading “one stop†provider of logistical services and financing to imported car dealers nationwide. The Company has made the strategic decision to deemphasize imported auto unit sales in favor of expanding its new, highly profitable domestic auto websites, currently in 12 cities and accessible through its national website, www.at160.com, launched in May, 2009. Already contributing significantly to profits, the Company believes further expansion of its websites, including new web-based auto-related services, will drive future growth. | |||
 | |||
 | |||
Company: | China Biologic Products, Inc. | ||
Ticker Symbol & Exchange: | CBPO.OB | ||
Investor Relations Contact: | Crocker Coulson | ||
Investor Relations Contact Phone: | 646 213 1915 | ||
Web: | http://www.chinabiologic.com/ | ||
Date of Presentation: | 09/10/09 | ||
 | |||
China Biologic Products, Inc. (CBPO.OB) through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd. (“Taibangâ€) and Chongqing Dalin Biologic Technologies Co., Ltd. (“Dalinâ€) and its equity investment in Xi’an Huitian Blood Products Co., Ltd. (“Huitianâ€), is currently the largest non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. The company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. Blood products are biological products used in biological active preparation to collect healthy blood for raw materials, which are manufactured through biological processes or separation and purification technologies. | |||
 | |||
 | |||
Company: | China-Biotics, Inc. | ||
Ticker Symbol & Exchange: | CHBT (NASDAQ GM) | ||
Investor Relations Contact: | Crocker Coulson | ||
Investor Relations Contact Phone: | 1 646-213-1915 | ||
Web: | www.chn-biotics.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Headquarterd in Shanghai, China-Biotics was founded in 1999 and is one of China's largest suppliers of probiotics. Probiotics are beneficial live bacteria used in dietary supplements and food additives to improve intestinal health and digestion. The Company's product portfolio contains live microbials made with proprietary technology. These products are sold over-the-counter under the "Shining" brand through large distributors to more than 1,000 pharmacies and 100 supermarkets in Shanghai, Jiangsu, Zhejiang and Hong Kong.. Shining is one of the most recognized brands in Shanghai. There is significant demand for probiotics for use in bulk additive market, which is currently met by imports. China-Biotics has built up a new plant with 150 metric ton annual capacity that will increase its production capacity manyfold to capture this market | |||
 | |||
 | |||
Company: | China Carbon Graphite Group | ||
Ticker Symbol & Exchange: | CHGI - OTCBB | ||
Investor Relations Contact: | Capital Group Communications | ||
Investor Relations Contact Phone: | Kevin Fickle /Mark Bernhard -415-332-7200 | ||
Web: | chinacarboninc.com | ||
Date of Presentation: | Thursday, September 10th, 12:30PM | ||
 | |||
One of China's largest producers and wholesale suppliers of fine grain and high purity graphite. 2008 Earnings $.21 share. | |||
 | |||
Recent Events: | |||
Retired 5,875,000 warrants through issuance of 887,500 common shares. 14,672,970 common shares outstanding. | |||
 | |||
Final approval & funding of $26,000,000 (US) loan from Chinese Central Government's economic stimulus plan expected within 60 days. Company will double production capacity to 30,000 metric tons annually, develop and produce nuclear grade graphite for 40 nuclear reactors Chinese government building by 2015. Each reactor requires 10,000 metric tons of nuclear graphite @ $1,500 ton averaging $150,000,000 (US). | |||
 | |||
Company actively seeking same sector acqusitions in China. | |||
 | |||
 | |||
Company: | China Energy Recovery, Inc. | ||
Ticker Symbol & Exchange: | CGYV.OB | ||
Investor Relations Contact: | Jim Blackman | ||
Investor Relations Contact Phone: | 713-256-0369 | ||
Web: | http://www.chinaenergyrecovery.com | ||
Date of Presentation: | September 10, 2009 (Thursday) | ||
 | |||
CER is an international leader in designing, manufacturing and installing waste heat energy recovery systems which provide facilities with greater energy efficiency. The company's primary focus is on the Chinese market. CER's technology captures industrial waste energy to produce low-cost electrical power, enabling industrial manufacturers to reduce their energy costs, shrink their emissions footprint, and generate sellable emissions credits. CER has deployed its systems throughout China and in such international markets as Egypt, Korea, Vietnam and Malaysia. CER focuses on numerous industries in which a rapid payback on invested capital is achieved by its customers, including: chemical, paper manufacturing, refining (including methanol refining), etc. CER continues to invest in R&D and plans to build China's first state-of-the-art energy recovery system research and fabrication facility to allow it to meet the increased demand for its products and services. For more information on CER, please visit: |
|||
http://www.chinaenergyrecovery.com/s/Home.asp. |
|||
 | |||
 | |||
Company: | China Information Security Technology, Inc. | ||
Ticker Symbol & Exchange: | Nasdaq: CPBY | ||
Investor Relations Contact: | Iris Yan | ||
Investor Relations Contact Phone: | 86-755-83704767 | ||
Web: | www.chinacpby.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
China Information Security Technology, Inc. headquartered in Shenzhen, China, is a leading application software developer, systems integrator and full-service Geographic Information Systems (“GISâ€) solutions provider to the public security and civil-use markets in China, aiming to use information technology to improve public safety and information management. Its main business lines range from digital information security, to GIS solutions, and digital hospital information systems. The Company provides a broad portfolio of fully integrated solutions and services, including its First Responder Coordination Platform, Intelligent Border Control System, Residence Card Information Management System, Digital Hospital Information System and Police- and Civil-use GIS products, to serve the growing demand for digital hospital and electronic medical record systems in China. Its commitment to leading-edge technology and quality assurance has won the Company numerous government and enterprise contracts throughout China. | |||
 | |||
 | |||
Company: | China North East Petroleum Holdings Ltd. | ||
Ticker Symbol & Exchange: | NYSE Amex: NEP | ||
Investor Relations Contact: | Chao Jiang | ||
Investor Relations Contact Phone: | 212-307-3568 | ||
Web: | www.cnepetroleum.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
China North East Petroleum Holdings Limited is an independent oil company that engages in oil drilling project management and the production of crude oil in proven oilfields in Northern China. The Company is a pioneer in China’s private oil exploration and production industry, and the first Chinese non-state-owned oil company trading on the NYSE Amex. | |||
 | |||
The Company has a lease and sales contract with the PetroChina to sell its produced crude oil for use in the China marketplace. The Company currently operates four oilfields in Northern China. For more information about the Company, please visit http://www.cnepetroleum.com | |||
 | |||
 | |||
Company: | China Sky One Medical, Inc. | ||
Ticker Symbol & Exchange: | NASDAQ: CSKI | ||
Investor Relations Contact: | Mr. Stanley Hao | ||
Investor Relations Contact Phone: | 86-451-53994069 | ||
Web: | www.cski.com.cn | ||
Date of Presentation: | September 10th, 2009 | ||
 | |||
China Sky One Medical, Inc. manufactures, markets and distributes branded pharmaceutical products mainly for external use, including Chinese medicines, western medicines, diagnostic kits and cosmetics. Its “Kang Xi†and “Yu Fu†trademarks are well known for high quality and value in China. The Company’s distribution network covers approximately 5500 retail stores and hospitals in 24 provinces of China and 20 other countries and regions. Its leading products include its Sumei Slim Patch for weight loss, its Anti-hypertension Patch, its Compound Camphor Cream for treating dermatitis, and other various drops and ointments. | |||
 | |||
 | |||
Company: | China Technology Development Group Corp. | ||
Ticker Symbol & Exchange: | CTDC | ||
Investor Relations Contact: | [email protected] | ||
Investor Relations Contact Phone: | 852-3112 8461, +86-2669 8709 | ||
Web: | www.chinactdc.com | ||
Date of Presentation: | September 10th 2009 | ||
 | |||
China Technology Development Group Corporation (NASDAQ:CTDC) (“the Company†or “CTDCâ€) is an integrated green energy group, focusing on the provision of solar energy products and solutions in China. | |||
 | |||
The Company’s major shareholders include China Merchants Group, one of the biggest state-owned conglomerates in China, and Beijing Holdings Limited, the largest integrated conglomerate owned and operated by Beijing Municipal Government outside Mainland China. | |||
 | |||
CTDC is expanding its business through merger and acquisition in Chinese new energy industry, and committed to building a greener world by bringing clean and affordable energy to every family in China. | |||
 | |||
 | |||
Company: | China TransInfo Technology Corporation | ||
Ticker Symbol & Exchange: | CTFO Nasdaq GM | ||
Investor Relations Contact: | Fan Zhou | ||
Investor Relations Contact Phone: | 86 10 8267 1299 - 8033 | ||
Web: | www.chinatransinfo.com | ||
Date of Presentation: | September 10th 9:10am ET | ||
 | |||
China TransInfo is primarily focused on providing transportation information services and comprehensive solutions based on GIS technologies. The Company aims to become the largest transportation information products and comprehensive solutions provider, as well as the largest real time transportation information platform operator and provider in China. The Company owns software copyrights for 75 software products and has won 5 of the 10 model cases sponsored by the PRC Ministry of Communications. The Company’s affiliation with Peking University provides the Company access to the University’s GeoGIS Research Laboratory, including 30 Ph.D. researchers. As a result, the Company is playing a key role in setting the standards for electronic transportation information solutions. | |||
 | |||
 | |||
Company: | China Wind Systems, Inc. | ||
Ticker Symbol & Exchange: | CWSI OTC BB | ||
Investor Relations Contact: | Crocker Coulson | ||
Investor Relations Contact Phone: | 646-213-1915 | ||
Web: | www.chinawindsystems.com | ||
Date of Presentation: | September 11, 2009 10:25 a.m. ET | ||
 | |||
China Wind Systems supplies forged rolled rings to the wind power and other industries and industrial equipment to the textile and energy industries in China. With its newly finished state-of-the-art production facility, the Company is expected soon to significantly increase its shipment of high-precision rolled rings and other essential components primarily to the wind power and other industries. | |||
 | |||
 | |||
Company: | China XD Plastics Company Ltd. | ||
Ticker Symbol & Exchange: | CXDC.OB | ||
Investor Relations Contact: | Crocker Coulson | ||
Investor Relations Contact Phone: | 646 213 1915 | ||
Web: | http://www.chinaxd.net/ | ||
Date of Presentation: | 09/10/09 | ||
 | |||
China XD Plastics Company Ltd., through its wholly owned subsidiary Harbin Xinda Macromolecule Material (“Xindaâ€), develops, manufactures, and distributes modified plastics, primarily for automotive applications. The Company’s specialized plastics are used in the exterior and interior trim and in the functional components of more than 30 automobile brands manufactured in China, including Audi, Red Flag, Volkswagen, and Mazda. China XD currently has the largest production base of modified plastics for automotive applications in China. It now has 396 full-time employees and is headquartered in Harbin, Heilongjiang Province, in Northeast China. | |||
 | |||
 | |||
Company: | CHINA YOUTH MEDIA, INC. | ||
Ticker Symbol & Exchange: | OTC BB: CHYU | ||
Investor Relations Contact: | Sophia Kim; American Capital Ventures | ||
Investor Relations Contact Phone: | (310) 728-1457;(305) 918-7000 | ||
Web: | www.ChinaYouthMedia.com | ||
Date of Presentation: | September 9, 2009 9:35AM-10:00AM | ||
 | |||
China Youth Media, Inc., a youth marketing and media company, delivers advertising and content in the People’s Republic of China. The company provides advertisers and corporations with direct and centralized access to China’s highly valuable student population, which constitutes a key segment of the world’s largest youth market. China Youth Media has secured an exclusive 30-year contract with the Chinese government controlled corporation, China Youth Interactive, which grants the company a broad range of rights to market to China's 30 million plus college students with preferred access online, on campus and via mobile. The company offers this unprecedented access through a campus media network consisting of an Intranet Television Network and media portal called Koobee, sponsored campus events and advanced mobile marketing. | |||
 | |||
 | |||
Company: | ChinaNet Online Holdings, Inc. | ||
Ticker Symbol & Exchange: | CHNT OTCBB | ||
Investor Relations Contact: | HC International, Inc. | ||
Investor Relations Contact Phone: | Ted Haberfield, 760-755-2716 | ||
Web: | www.chinanet-online.com | ||
 | |||
ChinaNet Online Holdings, Inc. (OTCBB:CHNT), through its wholly owned subsidiary, China Net Online Media Group Limited (the “China Netâ€), a leading full-service media development, advertising and communications company for small and medium companies (SME’s) in China. Founded in 2003 and based in Beijing, PRC, the Company provides internet advertising and other services for Chinese SME’s via its well recognized portal website 28.com, TV commercials and program production via the China-Net TV, and in-house LCD advertising on banking kiosks targeting Chinese banking patrons. | |||
 | |||
 | |||
Company: | Cipher Pharmaceuticals Inc. | ||
Ticker Symbol & Exchange: | DND | ||
Investor Relations Contact: | Craig Armitage | ||
Investor Relations Contact Phone: | 416-815-0700 x 278 | ||
Web: | www.cipherpharma.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Cipher is a drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. The Company's lead compound, CIP-FENOFIBRATE, received final approval from the U.S. FDA and Health Canada in 2006. The product is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen(R). In addition, Cipher is developing formulations of the pain reliever tramadol (tentative FDA approval in February 2009) and the acne treatment isotretinoin (FDA approvable letter in April 2007). | |||
 | |||
 | |||
Company: | City Telecom | ||
Ticker Symbol & Exchange: | CTEL NASDAQ | ||
Investor Relations Contact: | John Marco | ||
Investor Relations Contact Phone: | 310-819-2948 | ||
Web: | http://www.ctigroup.com.hk/en/about.html | ||
Date of Presentation: | Sept 10th 2009 | ||
 | |||
City Telecom has built the most extensive and fastest, end-to-end fiber network in Hong Kong. The Company has established solid market position as the second largest and fastest growing broadband service provider in the country. It is aggressively expanding its market penetration, taking market share away from competitors, in an effort to become the largest IP service provider in Hong Kong’s $3.6B market by 2016. Moreover, with its high speed FTTH network, low churn rate and commitment to customer service, City Telecom has been able to increase its average revenue per user and margins. | |||
 | |||
 | |||
Company: | Clarient, Inc. | ||
Ticker Symbol & Exchange: | NASDAQ: CLRT | ||
Investor Relations Contact: | Matt Clawson | ||
Investor Relations Contact Phone: | 9494/474-4300 | ||
Web: | www.clarientinc.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient aims to become the leader in cancer diagnostics by translating cancer discovery into improved patient care. Clarient’s principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. Clarient is a centralized resource for leading diagnostic technologies, having created a state-of-the-art commercial cancer laboratory providing the most advanced diagnostic services available onsite and over the web. Resulting diagnostic reports and analyses are made available to customers through Clarient’s Internet-based portal, PATHSiTE.™ Clarient also plans to develop and market new, proprietary “companion†diagnostic markers for numerous cancers. | |||
 | |||
 | |||
Company: | CNS Response, Inc. | ||
Ticker Symbol & Exchange: | CNSO | ||
Investor Relations Contact: | Marty Tullio | ||
Investor Relations Contact Phone: | 949-553-9748 | ||
Web: | www.cnsresponse.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Today physicians base treatments on objective test data provided by blood tests, MRIs or X-Rays. Even though CNS drugs represent the largest drug class, similar objective data have not been available to physicians prescribing them —until now! | |||
 | |||
CNSO is a life-sciences data company with a new prescription to personalize medication management: a patented biomarker system comparing individual patient EEGs with a reference outcome database. The result: a 2-page report that provides physicians guidance with individualized medication options for his patient. We call it referenced-EEG (rEEG®), and it’s shown extraordinary results in eleven clinical trials and case series. | |||
 | |||
 | |||
Company: | CO2 Solution Inc. | ||
Ticker Symbol & Exchange: | TSX Venture: CST | ||
Investor Relations Contact: | Glenn Kelly | ||
Investor Relations Contact Phone: | 418-842-3456, ext. 205 | ||
Web: | www.co2solution.com | ||
Date of Presentation: | September 9, 2009 at 10:00AM | ||
 | |||
CO2 Solution Inc. has developed a proprietary bio-technological platform for the efficient capture of carbon dioxide (CO2), the most important greenhouse gas (GHG), from coal fired power plants and other emitters. The Company’s technology platform exploits a bio-catalyst (enzyme), carbonic anhydrase, which functions within humans and other mammals to manage CO2 during respiration. CO2 Solution has adapted the enzyme to function within an industrial environment, and thus has taken advantage of a biomimetic approach to CO2 capture based on millions of years of evolution. The Company is commercializing its technology for coal fired power generation, the oil sands and other CO2-intensive industries where a low-cost capture solution is key to meeting climate change legislation in a cost effective manner. | |||
 | |||
 | |||
Company: | Coastal Contacts Inc | ||
Ticker Symbol & Exchange: | COA: TSX | ||
Investor Relations Contact: | Terry Vanderkruyk | ||
Investor Relations Contact Phone: | 604-676-4498 | ||
Web: | www.coastalcontacts.com | ||
Date of Presentation: | Wednesday, September 9th 5:20pm | ||
 | |||
Coastal Contacts is the world’s largest online vision care supplier. Providing contact lenses, eyeglasses and other complimentary vision care products to consumers worldwide, Coastal Contacts is proud to provide an affordable, convenient option for high quality vision care products. With its world class operations in North America, Europe and Asia, Coastal Contacts offers a unique blend of private label and branded products to over 150 countries across the globe. Already #1 in many of its markets, Coastal is rapidly advancing toward its goal of becoming the “World’s Optical Store.†| |||
 | |||
 | |||
Company: | Columbia Laboratories, Inc. | ||
Ticker Symbol & Exchange: | Nasdaq: CBRX | ||
Investor Relations Contact: | Melody Carey | ||
Investor Relations Contact Phone: | 917-322-2571 | ||
Web: | www.columbialabs.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Columbia Laboratories, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the women’s healthcare and endocrinology markets that use its novel bioadhesive drug delivery technology. Columbia’s U.S. sales organization markets CRINONE® 8% (progesterone gel) in the United States for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and STRIANT® (testosterone buccal system) for the treatment of hypogonadism in men. The Company’s partners market CRINONE® 8%, STRIANT® and three other products to additional U.S. and foreign markets. | |||
 | |||
 | |||
Company: | Copper Mountian Mining Corporation | ||
Ticker Symbol & Exchange: | CUM (TSX) | ||
Investor Relations Contact: | Don Graham | ||
Investor Relations Contact Phone: | 604.682.2992 ext: 225, [email protected] | ||
Web: | www.CuMtn.com | ||
Date of Presentation: | September 9th, 4:05pm | ||
 | |||
Copper Mountain Mining (TSX:CUM) has partnered with Mitsubishi Materials Corporation to bring back into production the Copper Mountain Project, by mid-2011. The Project is owned 75% by Copper Mountain Mining Corporation and 25% by Mitsubishi Materials Corporation. | |||
 | |||
The Company completed an independent feasibility study that confirmed the economic viability of bringing back into production a conventional open pit mine with a 35,000 tonnes per day mill. The mine, with a resource of 5 billion pounds of Copper, is designed to produce approximately 100 million pounds of copper per year in a copper concentrate with gold and silver credits. | |||
 | |||
 | |||
Company: | Cortex Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | COR | ||
Investor Relations Contact: | Dian Griesel, IRG, New York | ||
Investor Relations Contact Phone: | 212-825-3210 | ||
Web: | www.cortexpharm.com | ||
Date of Presentation: | Thursday, September 10, 2009 | ||
 | |||
Cortex Pharmaceuticals, Inc. is a neuroscience company focused on the development of AMPAKINE® compounds, a technology that acts on the AMPA receptor system of neurons in the brain to up-regulate signaling between brain cells. The compounds are small, orally active molecules, which can be used to treat ADHD, Alzheimer’s, Huntington’s, Fragile X and Rett’s syndromes and also depression and schizophrenia. Cortex has two lead compounds, CX1739, currently being evaluated in a Phase II study of sleep apnea and CX717 which has shown positive results in the treatment of drug induced respiratory depression and in ADHD in adult patients. | |||
 | |||
 | |||
Company: | Cyber Digital, Inc. | ||
Ticker Symbol & Exchange: | CYBD (OTC) | ||
Investor Relations Contact: | J.C. Chatpar | ||
Investor Relations Contact Phone: | 631-231-1200 | ||
Web: | www.cyberdigitalinc.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Cyber Digital designs and develops a vast array of software based digital switching systems and Internet Protocol (IP) broadband infrastructure systems for network operators worldwide. Cyber Digital's mission is to become a major network operator offering managed broadband, VoIP and VPN services in unserved and underserved areas in the U.S. by deploying its systems with the support of federal government grants funded by the American Recovery and Reinvestment Act of 2009. While stimulating economies in these areas, it generates recurring revenues from selling its services to small businesses, residential customers and anchor institutions such as hospitals, schools and public safety facilities. | |||
 | |||
 | |||
Company: | CyberDefender Corporation | ||
Ticker Symbol & Exchange: | OTCBB:CYDE | ||
Investor Relations Contact: | Kevin Harris | ||
Investor Relations Contact Phone: | 213-689-8631 x127 | ||
Web: | www.cyberdefender.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
CyberDefender Corporation (OTCBB:CYDE), is a rapidly growing provider of cyber-security software and services to consumers. CyberDefender antispyware, antivirus and identity protection products are based on its patent-pending peer to peer earlyNETWORK technology. In addition, CyberDefender markets PC optimization software and Live Help Desk services. Through its multi-channel marketing approach utilizing web, search, direct response tv and radio advertising and retail distribution --CyberDefender is on track to reach over one million subscribers by 2010. To date, more than 15 million consumers have used CyberDefender products and services. For additional information: www.cyberdefender.com. | |||
 | |||
 | |||
Company: | Cyclacel Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | CYCC | ||
Investor Relations Contact: | Corey Sohmer | ||
Investor Relations Contact Phone: | 908-517-7330 | ||
Web: | www.cyclacel.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of elderly AML, MDS, NSCLC and in Phase 1 in combination with seliciclib. Seliciclib, a CDK inhibitor, is in Phase 2 for the treatment of lung and nasopharyngeal cancers. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. ALIGN markets in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Lozenges for xerostomia. | |||
 | |||
 | |||
Company: | Cytori Therapeutics, Inc. | ||
Ticker Symbol & Exchange: | NASDAQ: CYTX | ||
Investor Relations Contact: | Tom Baker | ||
Investor Relations Contact Phone: | 858.875.5258 | ||
Web: | www.cytoritx.com | ||
Date of Presentation: | September 20, 2009, 10:50-11:15 AM | ||
 | |||
Cytori is committed to providing patients and physicians around the world with medical technologies, which harness the potential of adult stem and regenerative cells from adipose tissue. With the introduction of a family of medical devices, we have made a patient’s own clinical grade stem and regenerative cells available to them at the point-of-care. | |||
 | |||
The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets, while we seek regulatory clearance in the United States. Our StemSource® product line is sold globally for cell banking and research applications. | |||
 | |||
Our product development pipeline spans cardiovascular disease, renal failure, pelvic health among other acute and chronic conditions. | |||
 | |||
 | |||
Company: | CytRx Corporation | ||
Ticker Symbol & Exchange: | NASDAQ: CYTR | ||
Investor Relations Contact: | Thomas Wagner | ||
Investor Relations Contact Phone: | 800-385-5790 x152, 718-233-2600 x152 | ||
Web: | www.cytrx.com | ||
Date of Presentation: | September 9, 2009 at 2:25 p.m. ET | ||
 | |||
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the treatment of acute promyelocytic leukemia (APL). In addition, CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. CytRx also maintains a 39% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII). | |||
 | |||
A webcast of the CytRx presentation will be posted to the Company's Web site at www.cytrx.com. | |||
 | |||
 | |||
Company: | Delcath Systems, Inc. | ||
Ticker Symbol & Exchange: | DCTH | ||
Investor Relations Contact: | EVC Group | ||
Investor Relations Contact Phone: | EVC Group, Doug Sherk, 415-896-6491 | ||
Web: | www.delcath.com | ||
Date of Presentation: | Friday, Sept. 11th | ||
 | |||
Delcath Systems (Nasdaq:DCTH) is at the forefront of the regional treatment of cancer with a promising therapy to shrink tumors in the liver. Delcath’s Percutaneous Hepatic Perfusion (PHP™) technology allows physicians to deliver significantly higher doses of anti-cancer drugs to the liver without exposing the patient's entire body to those same potent levels of drug. PHP™ is an investigational treatment currently undergoing testing in Phase III and Phase II clinical trials. |
|||
 | |||
 | |||
Company: | Depomed, Inc. | ||
Ticker Symbol & Exchange: | DEPO NASDAQ | ||
Investor Relations Contact: | DeDe Sheel, FD | ||
Investor Relations Contact Phone: | 415 293 4412 | ||
Web: | www.depomed.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Depomed is an innovative specialty pharmaceutical company focused on improving the efficacy, safety, and patient compliance of compounds across key therapeutic categories with a long term focus on woman’s health. Since its founding in August 1995, the company has advanced two products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations. The company utilizes its proven, proprietary AcuForm(TM) drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. | |||
 | |||
 | |||
Company: | East Asia Minerals Corporation | ||
Ticker Symbol & Exchange: | EAS: TSXV | ||
Investor Relations Contact: | Nick Kohlmann | ||
Investor Relations Contact Phone: | (416) 792-8734 | ||
Web: | www.EAminerals.com | ||
Date of Presentation: | Thursday, September 10, 2009 | ||
 | |||
East Asia Minerals (EAS-TSXV) is an Asian-based, Canadian mineral exploration company with gold and copper exploration properties in Indonesia, and uranium exploration properties in Mongolia. In Indonesia the Company has a 70 to 85% interest in six advanced gold and gold-copper properties located in Aceh Province, Sumatra, and Sangihe Island, North Sulawesi. Two of these, the Sangihe (Binebase-Bawone) and Barisan 1 (Abong) gold projects, are being advanced to define NI43-101 compliant resources. The Company owns eleven uranium properties, including the advanced Ingiin-Nars, Ulaan Nuur and Enger uranium projects and four phosphate properties in Mongolia. East Asia currently has 65,365,372 shares outstanding. | |||
 | |||
 | |||
Company: | eMagin Corporation | ||
Ticker Symbol & Exchange: | EMAN | ||
Investor Relations Contact: | Paul Campbell, CFO & Treasurer | ||
Investor Relations Contact Phone: | 425-749-3600 | ||
Web: | www.emagin.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
eMagin Corporation is a leader in OLED (organic light emitting diode) technology. We design, develop, manufacture, and market OLED on silicon microdisplays, virtual imaging products which utilize OLED microdisplays, and related products. Our virtual imaging products integrate OLED, technology with silicon chips to produce high-resolution microdisplays smaller than one-inch diagonally which, when viewed through a magnifier, create virtual images that appear comparable in size to that of a computer monitor or a large-screen television. Our products enable our original equipment manufacturer (“OEMâ€) customers to develop and market improved or new electronic products. | |||
 | |||
 | |||
Company: | EMRISE CORPORATION | ||
Ticker Symbol & Exchange: | NYSE ARCA: ERI | ||
Investor Relations Contact: | Rene Caron | ||
Investor Relations Contact Phone: | 9494/474-4300 | ||
Web: | www.emrise.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
EMRISE designs, manufactures and markets electronic devices, sub-systems and equipment for aerospace, defense, industrial and communications markets. Its products perform power supply and power conversion; radio frequency (RF) and microwave signal processing; and network access and timing and synchronization of communications networks. Primary growth drivers include using its RF devices in radio-controlled improvised explosive device jamming systems, and its Network Timing and Synchronization products in edge networks. EMRISE serves customers in North America, Europe and Asia, including most of the Fortune 100 in the U.S. doing business in EMRISE’s markets and similar-size companies in Europe and Asia, through its operations in the U.S., England and France. | |||
 | |||
 | |||
Company: | Emisphere Technologies, Inc. | ||
Ticker Symbol & Exchange: | OTC BB: EMIS | ||
Investor Relations Contact: | Michael Garone | ||
Investor Relations Contact Phone: | (973) 532-8005 | ||
Web: | http://www.emisphere.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its Eligen® Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen® Technology can be applied to oral formulations as well as other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. | |||
 | |||
 | |||
Company: | Evans Bancorp, Inc. | ||
Ticker Symbol & Exchange: | EVBN: Nasdaq | ||
Investor Relations Contact: | Deborah Pawlowski | ||
Investor Relations Contact Phone: | 716-843-3809 | ||
Web: | www.evansbancorp.com | ||
Date of Presentation: | 09.11.2009 | ||
 | |||
Evans Bancorp, Inc. is a financial holding company and the parent company of Evans Bank, N.A., a commercial bank with $553 million in assets and $451 million in deposits at June 30, 2009. The bank has 13 branches located in Western New York. Evans National Leasing, Inc., an indirect wholly-owned subsidiary of Evans Bank is a general business equipment leasing company with customers throughout the U.S. Evans Bancorp's wholly-owned insurance subsidiary, The Evans Agency, provides retail property and casualty insurance through 15 insurance offices in the Western New York region. Evans Investment Services, a wholly-owned subsidiary of Evans Bank, provides non-deposit investment products such as annuities and mutual funds. | |||
 | |||
 | |||
Company: | Exco Resources Ltd (“Excoâ€) | ||
Ticker Symbol & Exchange: | EXS (ASX) – Listed 1998 | ||
Investor Relations Contact: | Mr Michael Anderson (Managing Director) | ||
Investor Relations Contact Phone: | 61 (0)412 496 797 | ||
Web: | www.excoresources.com.au | ||
Date of Presentation: | 10th of September 2009, 4.30pm – 4.55pm, Homes II Salon (4th Floor, New York Palace Hotel) | ||
 | |||
Exco is focused on developing its portfolio of Australian-based copper and gold projects. | |||
 | |||
In NW Queensland Exco holds a ~4,100km2 land package, in the highly prospective Mt Isa Block. Feasibility studies are underway on the Cloncurry Copper Project, whilst the Hazel Creek Project offers substantial exploration upside. To date Exco has established a resource base of 57Mt containing 495,000t of copper and 480,000oz of gold. | |||
 | |||
In South Australia Exco is developing the White Dam Project. Approvals and funding arrangements are in place for an operation that will produce ~120,000oz of gold over a 2 ½ year period. Site works are underway with first production targeted in Q1/2010. | |||
 | |||
 | |||
Company: | Exeter Resource Corporation | ||
Ticker Symbol & Exchange: | NYSE-AMEX: XRA | ||
Investor Relations Contact: | Rob Grey | ||
Investor Relations Contact Phone: | 888 688 9592 | ||
Web: | www.exeterresource.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Exeter Resource Corporation is one of the most active exploration and mine development companies operating in South America. The Company has C$30 million in cash, no debt and two principal assets. The Caspiche gold-copper porphyry discovery and the Cerro Moro high-grade gold-silver deposit. | |||
 | |||
Caspiche’s initial NI43-101 compliant inferred mineral resource estimate totals 8.7 million ounces gold and 2.1 billion pounds of copper*.A second mineral resource estimateis expected to be available in September 2009. | |||
 | |||
Cerro Moro’s initial NI43-101 compliant inferred resource estimate totals 646,000 ounces gold equivalent**, at a grade of 18 grams per tonne gold equivalent** (0.52 ounces per ton). | |||
 | |||
The focus will be on advancing the Escondida vein which contains 518,000 ounces gold equivalent** at a grade of 34 g/t gold equivalent** (0.99 ounces per ton) |
|||
 | |||
 | |||
Company: | First Ship Lease Trust | ||
Ticker Symbol & Exchange: | D8DU, SGX-ST | ||
Investor Relations Contact: | Fung-Leng, Chen (Mr) | ||
Investor Relations Contact Phone: | [email protected], 65 96853910 | ||
Web: | www.FSLTrust.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
First Ship Lease Trust (“FSL Trustâ€) (SGX: D8DU, OTCQX-ADR: FSHPY) owns a portfolio of 23 vessels which are leased to maritime companies on long-term bareboat charters. The portfolio is broadly-diversified across five shipping sub-sectors and eight lessees. The portfolio has an average remaining lease of eight years and contracted revenue of about US$800 million as at 30 June 2009. | |||
 | |||
FSL Trust is managed by FSL Trust Management Pte Ltd, the Trustee-Manager. The Trustee-Manger is focused on growing and diversifying FSL Trust’s portfolio through cash flow accretive acquisitions with long-term bareboat charters that support regular and stable distributions to its unitholders. | |||
 | |||
 | |||
Company: | FX Energy, Inc. | ||
Ticker Symbol & Exchange: | fxen: Nasdaq | ||
Investor Relations Contact: | Scott J. Duncan | ||
Investor Relations Contact Phone: | 801 486-5555 | ||
Web: | www.fxenergy.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
FX Energy is an independent gas and oil exploration and production company with its principal production, reserves, and exploration activities in Poland. Relatively little gas has been discovered in Poland’s sector of the North European Permian Basin compared to the UK, Dutch and German sectors. Consequently, management believes the Polish Permian Basin is under explored and under exploited and offers high potential for discovering significant amounts of hydrocarbons. Based on this thesis, FX Energy has acquired 4.9 million net acres in Poland, generated a number of attractive prospects, drilled several successful wells and established reserves and cashflow for its shareholders. | |||
 | |||
 | |||
Company: | Gadot Chemical Tankers & Terminals Ltd. | ||
Investor Relations Contact: | Amit Magen | ||
Investor Relations Contact Phone: | 972-9-890-9500 | ||
Web: | www.gadot.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Gadot is Israel’s leading chemical supply chain & distribution corporation. Through its subsidiaries, Gadot ships, stores, and distributes liquid chemicals, specialty chemicals, oils and related materials worldwide. Founded in 1958 as a chemical importer, Gadot expanded to offer its clients a full range of services, delivering value to customers across the chemical value chain, from acquiring customer-specific chemicals, logistical handling including shipping and transport, offloading, storage and delivery. Gadot’s operations include the import, marketing and sales of chemicals and other raw materials in Israel and Europe. The company is currently expanding its chemical supply chain operations globally, with emphasis on green chemistry. | |||
 | |||
Gadot is a fully owned subsidiary of Ampal which is dual-listed on NADAQ and Tel Aviv exchange. | |||
 | |||
 | |||
Company: | General Steel Holdings, Inc. | ||
Ticker Symbol & Exchange: | NYSE: GSI | ||
Investor Relations Contact: | Jessica Barist Cohen | ||
Investor Relations Contact Phone: | Ogilvy Financial, New York 646-460-9989 | ||
Web: | www.gshi-steel.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
General Steel Holdings, Inc., (NYSE: GSI), headquartered in Beijing, China, operates a diverse portfolio of Chinese steel companies. With 6.3 million metric tons aggregate production capacity, its companies serve various industries and produce a variety of steel products including rebar, hot-rolled carbon and silicon sheet, high-speed wire and spiral-weld pipe. General Steel Holdings, Inc. has steel operations in Shaanxi and Guangdong provinces, Inner Mongolia Autonomous Region and Tianjin municipality. For more information, please visit www.gshi-steel.com. | |||
 | |||
 | |||
Company: | Genetix Group plc | ||
Ticker Symbol & Exchange: | GTX.L | ||
Investor Relations Contact: | Jonathan Birt, Fin Dynamics | ||
Investor Relations Contact Phone: | 44 20 7269 7205 | ||
Web: | www.genetix.com | ||
Date of Presentation: | 9th August, 4.30pm | ||
 | |||
Genetix is a leading provider of solutions for imaging and intelligent image analysis in the life science and clinical markets. The Gourp's systems are used in mainstream research, in the development of pharmaceuticals and biotherapeutics, and in clinical diagnostics. In April 2009 they acquired SlidePath Ltd, a company developing and deploying web-enabled, enterprise-level solutions that support the growing demand for global, high throughput image and data handling in the digital pathology market. | |||
 | |||
Genetix is headquartered in New Milton, United Kingdom with direct sales in USA, major European markets and Japan, together with a wide distributor network. | |||
 | |||
 | |||
Company: | Genta Incorporated | ||
Ticker Symbol & Exchange: | GETA | ||
Investor Relations Contact Phone: | [email protected], 908-286-3980 | ||
Web: | www.genta.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Genta is a biopharmaceutical company focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor our research platform: DNA/RNA Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the lead compound of our DNA/RNA Medicines program. Genta has completed its Phase 3 trial of Genasense in advanced melanoma and will present results in the 4th quarter 2009. Our Small Molecule program is focused on tesetaxel, an orally absorbed taxane in Phase 2 clinical trials, and gallium products including Ganite® (gallium nitrate injection), which Genta markets exclusively in the U.S., and oral gallium-containing compounds that target patients with accelerated bone loss. |
|||
 | |||
 | |||
Company: | GeoResources, Inc. | ||
Ticker Symbol & Exchange: | GEOI | ||
Investor Relations Contact: | Cathy Kruse | ||
Investor Relations Contact Phone: | 701-572-2020 x113 | ||
Web: | www.georesourcesinc.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
GeoResources, Inc. owns and operates producing oil and gas properties in the Southwest, Gulf Coast and Williston Basin and conducts oil and gas exploration, development and production operations in these areas. Additionally, GeoResources’ wholly-owned subsidiary, Catena Oil & Gas LLC, is the general partner and operator for two institutionally funded partnerships. | |||
 | |||
GeoResources’ reserves, including its direct working interests and partnership interests, are estimated at 141.4 Bcfe, 49% oil and 75% proved developed. Current production is approximately 2,300 Bopd and 19.0 MMcfd for its direct interests plus 4.1 MMcfd in its partnerships. As of July 1, 2009, the Company controlled approximately 484,000 gross acres and 234,000 net acres. | |||
 | |||
 | |||
Company: | GeoVax Labs, Inc. | ||
Ticker Symbol & Exchange: | OTCB: GOVX | ||
Investor Relations Contact: | Leslie Loyet | ||
Investor Relations Contact Phone: | (312) 640-6672 | ||
Web: | www.geovax.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
GeoVax is a clinical stage biotechnology company whose primary goal is to test, license and commercialize its DNA (prime) and MVA (boost) vaccine regimen for diseases caused by Human Immunodeficiency Virus (HIV) and other infectious agents. The immediate mission is to seek expansion of the current clinical trial (phase 2a) for the preventative version of the vaccine to the “at risk†human population (phase 2b) and to shepherd a therapeutic trial (phase 1) in HIV-1 infected subjects, scheduled to begin early 2010. GeoVax's technology is exclusively licensed from Emory University and was developed in collaboration with Emory University's Vaccine Center, the National Institutes of Health (NIH) and the U.S. Centers for Disease Control and Prevention (CDC). | |||
 | |||
 | |||
Company: | GMX Resources Inc. | ||
Ticker Symbol & Exchange: | GMXR | ||
Investor Relations Contact: | Michael Rohleder, President | ||
Investor Relations Contact Phone: | 405.254.5838 | ||
Web: | www.gmxresources.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
GMXR is a ‘Pure Play’, E & P Company with one of the most leveraged Haynesville / Bossier Horizontal Shale Operations in East Texas. The Company has 465 Bcfe in proved reserves (YE2008), 94% of which are natural gas. The Company's proved reserves are 81% operated and consist of 763 gross / 521 net H/B Hz 80 acre un-drilled locations; 8 gross / 8 net H/B producers, and 324 gross / 186.9 net Cotton Valley Sand ("CVS") producers; 2,657 gross / 1,974 net CVS 20 acre un-drilled locations; and 45 gross / 37.5 net Travis Peak / Hosston Sands & Pettit producers. These multiple resource layers provide high probability and the potential for repeatable, organic growth. | |||
 | |||
 | |||
Company: | Gold Horse International, Inc. | ||
Ticker Symbol & Exchange: | GHII | ||
Investor Relations Contact: | Adam Wasserman, CFO | ||
Investor Relations Contact Phone: | 800-867-0078 Ext 702 | ||
Web: | www.goldhorseinternational.com | ||
Date of Presentation: | September 10 from 08:20 to 08:45 AM | ||
 | |||
Gold Horse International, Inc. is a multi-faceted business group specializing in high-growth industries in China, including construction, real estate and hospitality. Jin Ma Construction Co., Ltd. has been providing construction and general contractor services in Hohhot, Inner Mongolia, China, to both private developers and the local and regional governments since 1980. Jin Ma Hotel Co., Ltd. owns, operates and manages the Jin Ma Hotel, a full-service two-star hotel and banquet facility located in Hohhot. Jin Ma Real Estate develops residential and commercial properties in the competitive and growing real estate market in Hohhot. | |||
 | |||
 | |||
Company: | Gold One International limited | ||
Ticker Symbol & Exchange: | ASX/JSE: GDO | ||
Investor Relations Contact: | Ilja Graulich | ||
Investor Relations Contact Phone: | 27 83 604 0820 | ||
Web: | www.gold1.co.za | ||
Date of Presentation: | Thursday, 10 September 2009 | ||
 | |||
Gold One International Limited is an Australian and African gold resource company listed on the financial markets operated by ASX Limited and JSE Limited (ticker: GDO). The company was created via inward listing of Gold One on the JSE and the subsequent acquisition by Gold One of all the issued ordinary shares in Aflease by way of a scheme of arrangement. The company’s vision is to be the preferred gold exploration, development and mining company, aiming to provide superior returns to investors in global markets, supportive of junior gold mining companies. The company believes that value accretive geographical diversification is also key to managing risk and in line with this strategy will continue to review opportunities in its targeted destinations of Australia, North America and Southern Africa. | |||
 | |||
 | |||
Company: | Gold Resource Corporation | ||
Ticker Symbol & Exchange: | OTC BB: GORO | ||
Investor Relations Contact: | Jason Reid | ||
Investor Relations Contact Phone: | 719 330 0258 | ||
Web: | www.goldresourcecorp.com | ||
Date of Presentation: | Sept. 9, 2009 | ||
 | |||
Gold Resource Corporation is a mining company focused on production and pursuing development of select, high-grade gold and silver projects that feature low operation costs and produce high returns on capital. | |||
 | |||
The Company has 100% interest in four high-grade gold and silver properties in Mexico's southern state of Oaxaca. | |||
 | |||
Gold Resource Corporation is positioned to emerge as a low cost gold producer in 2009 and is engineered from day one to maximize shareholder value with a focus on cash flow and potential dividends. | |||
 | |||
 | |||
Company: | Golden Predator Royalty and Development | ||
Ticker Symbol & Exchange: | TSX.V:GPD | ||
Investor Relations Contact: | Ilona Stigrad | ||
Investor Relations Contact Phone: | 604-648-4653 | ||
Web: | www.goldenpredator.com | ||
Date of Presentation: | September 11th,2009 | ||
 | |||
Golden Predator's corporate mandate is to establish a self-fundedgold exploration company with an immediate focus on exploringand developing world class gold deposits in the Tintina Gold Belt and the Rocky Mountain Alkalic Gold Province. The Company seeks internal funding from high grade production in Nevada augmented by increasing royalty revenues. | |||
 | |||
In the Yukon’s prolific Tintina Gold Belt, the Company is currently drilling Gold Dome, Brewery Creek and Antimony Mountain. Golden Predator Royalty and Development Corp. continues to expand its interests in this area through exploration and property acquisition. In Nevada and Wyoming drilling plans progress on several advanced projects. | |||
 | |||
 | |||
Company: | Gulf Resources, Inc. | ||
Ticker Symbol & Exchange: | OTC BB: GFRE | ||
Investor Relations Contact: | David Wong, VP Finance | ||
Investor Relations Contact Phone: | Crocker Coulson, CCG - 1 (646) 213-1915 | ||
Web: | www.gulfresourcesinc.cn | ||
Date of Presentation: | 4:55 PM on Thu. Sept. 10, 2009 | ||
 | |||
Gulf Resources, Inc. (“Gulf Resources†or the “Companyâ€) is a leading provider of bromine and specialty chemical products in the People’s Republic of China (“PRCâ€). The Company operates through its two wholly-owned subsidiaries; Shouguang City Haoyuan Chemical Company Limited (“SCHCâ€), which primarily produces and distributes bromine and crude salt, and Shouguang Yuxin Chemical Industry Co., Limited (“SYCIâ€), which focuses on manufacturing and selling chemical products. Elemental bromine is used to manufacture a wide range of compounds utilized in chemical, manufacturing, pharmaceutical, and agricultural industries. The Company’s chemical products are currently utilized in a variety of applications, including oil and gas field exploration, papermaking chemical agents, and inorganic chemicals. | |||
 | |||
 | |||
Company: | Gulfstream International Airlines | ||
Ticker Symbol & Exchange: | GIA:AMEX | ||
Investor Relations Contact: | Jennifer K. Zimmons | ||
Investor Relations Contact Phone: | 212-838-1444 | ||
Web: | www.gulfstreamair.com | ||
Date of Presentation: | Sep 9th from 02:50 to 03:15 PM | ||
 | |||
Gulfstream International Airlines is a profitable regional air carrier based in Fort Lauderdale, Florida with 20 years operating experience. The Company specializes in providing travelers access to niche locations not typically covered by major carriers including: Bahamas, inter-Florida, Cuba, and the Cleveland area. With 150+ daily flights to second-tier routes in 21 cities, Gulfstream’s fleet of 19-seat planes, unique in-house technology platform, and marketing team makes the Company the dominant player in their space. Furthermore, the continuing retrenchment of other airlines to their hubs provides several additional lucrative city-to-city routes that would be otherwise unprofitable for other carriers. | |||
 | |||
 | |||
Company: | Guyana Goldfields Inc. | ||
Ticker Symbol & Exchange: | TSX. GUY | ||
Investor Relations Contact: | Jacqueline Wagenaar | ||
Investor Relations Contact Phone: | 416-628-5936 | ||
Web: | www.guygold.com | ||
Date of Presentation: | September 10, 2009 @ 10:50am | ||
 | |||
Guyana Goldfields Inc. is a well-financed Canadian-based junior mineral exploration company focused on the exploration and development of gold deposits in the mining-friendly Guiana Shield in South America with a land position totaling 350,000 acres in Guyana. The Company is currently undertaking technical studies to advance and develop its 100% interest in the Aurora Gold Project in Guyana with a current resource of 5.4 million oz. | |||
 | |||
GUY is currently utilizing six drills at site as part of the technical work for the feasibility study and continued exploration efforts. GUY is ready to start Development in Q2 2010 after completing the Economic and Social Impact Assessment, Definitive Feasibility Study, Permitting, and Project Financing. | |||
 | |||
 | |||
Company: | Hana Biosciences, Inc. | ||
Ticker Symbol & Exchange: | NASDAQ: HNAB | ||
Investor Relations Contact: | Rebecca Birbach | ||
Investor Relations Contact Phone: | 650-588-6641 | ||
Web: | http://www.hanabiosciences.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Hana Biosciences, Inc. (NASDAQ: HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best in-class team, accelerating the development of lead product candidates, expanding its pipeline by being an alliance partner of choice, and nurturing a unique company culture. | |||
 | |||
 | |||
Company: | Hecla Mining Company | ||
Ticker Symbol & Exchange: | HL:NYSE | ||
Investor Relations Contact: | Don Poirier, VP | ||
Investor Relations Contact Phone: | 208-769-4128 | ||
Web: | www.hecla-mining.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Established in 1891 in northern Idaho’s Silver Valley, Hecla has long been known in the United States as a quality producer of silver and gold. Hecla operates two underground mines, Lucky Friday in northern Idaho and Greens Creek near Juneau, Alaska, and is the oldest U.S.-based precious metals miner in North America. Hecla expects to produce 10-11 million ounces of silver in 2009 and also produces approximately 60,000 ounces of gold per year plus lead-zinc. Hecla has two development projects, San Juan Silver in Colorado and San Sebastian near Durango, Mexico. Hecla has highly prospective exploration opportunities in the camps where it operates as well as within the development projects in Colorado and Mexico. Hecla trades on the New York Stock Exchange and its stock symbol is “HL.†| |||
 | |||
 | |||
Company: | Helsinn Healthcare SA | ||
Investor Relations Contact: | Ricccardo Braglia | ||
Investor Relations Contact Phone: | 00 41 (0)91 985 21 21 | ||
Web: | www.helsinn.com | ||
Date of Presentation: | Sept. 9, 2009 4.05pm EDT (10.05pm Swiss time, 9.05pm UK time) | ||
 | |||
Helsinn Healthcare SA announced that Mr.Riccardo Braglia, CEO, will present an overview of the company, products and corporate goals at Rodman & Renshaw 11th Annual Healthcare Conference, New York, USA, on September 9th 2009 at 4:05pm EDT (10.05pm Swiss time, 9.05pm UK time). The presentation will be webcast live and can be accessed through the web site (www.wsw.com/webcast/rrshq15/helsinn) (available for 90 days). | |||
 | |||
Helsinn (www.helsinn.com) is a privately owned Swiss-based pharmaceutical group with subsidiaries in USA and Ireland. Core business: oncology, supportive care and pain inflammation. Business strategy: in-license early stage new chemical entities, complete their development up to market approvals and out-license to its worldwide network of partners. Active pharmaceutical ingredients and drug products are manufactured at Helsinn's cGMP facilities. | |||
 | |||
 | |||
Company: | Home BancShares, Inc. | ||
Ticker Symbol & Exchange: | HOMB / NASDAQ | ||
Investor Relations Contact: | Brian Davis | ||
Investor Relations Contact Phone: | 501-328-4770 | ||
Web: | www.homebancshares.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Home BancShares, Inc. is a bank holding company headquartered in Conway, Arkansas. The Company is primarily engaged in providing a full range of banking services to individual and corporate customers through its wholly owned community bank subsidiary – Centennial Bank. During 2009, the Company completed the combination of its former bank charters into a single charter, adopting Centennial Bank as the common name. The Bank has locations in central Arkansas, north central Arkansas, southern Arkansas, the Florida Keys and southwestern Florida. | |||
 | |||
 | |||
Company: | Hong Kong Highpower Technology, Inc. | ||
Ticker Symbol & Exchange: | NYSE Amex | ||
Investor Relations Contact: | Tricia Ross | ||
Investor Relations Contact Phone: | 916-939-7285 | ||
Web: | http://www.haopengbattery.com/ | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Hong Kong Highpower Technology is a profitable growth company that develops, manufactures and markets nickel-metal hydride (Ni-MH) and lithium-ion (Li-ion) rechargeable batteries and related products for consumer and industrial applications. The Company’s products are distributed worldwide for use in various electronic products and emergency power supplies such as digital and communication products, power tools, toys, notebook computers, cell phones, GPS navigation systems, military products, electronic bikes and medical devices. The Company’s manufacturing and product development facilities are located in Shenzhen, Guangdong Province, PRC, which facilitates low labor costs and easy access to land and raw materials, as well as additional cost and cycle time advantages garnered by proximity to electronics supply chains and end-markets. | |||
 | |||
 | |||
Company: | HORIZON FINANCIAL | ||
Ticker Symbol & Exchange: | NASDAQ GS: HRZB | ||
Investor Relations Contact: | Rich Jacobson, President & CEO | ||
Investor Relations Contact Phone: | 360-733-3050 | ||
Web: | www.horizonbank.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Horizon Financial Corp. is a $1.36 billion state-chartered bank holding company based in Bellingham, Washington. Its primary subsidiary, Horizon Bank, is a regional presence serving customers for 87 years operating 18 full-service offices; four commerical and real estate loan centers throughout Whatcom, Skagit, Snohomish and Pierce counties in Washington. | |||
 | |||
Selected Fiscal First Quarter 2010 Highlights include: | |||
 | |||
- Core Deposits generated year-over-year growth increasing $27.7 million compared to June of 2008, and increased $4.8 million since March, 2009. | |||
 | |||
- Total assets were $1.36 billion at 6/30/2009 | |||
 | |||
- Total risk-based capital ratio was 5.2% and Tier 1 capital ratio equaled 3.17% at 6/30/09. | |||
 | |||
- Horizon actively pursuing capital infusion. | |||
 | |||
 | |||
Company: | ImmunoCellular Therapeutics, Ltd. | ||
Ticker Symbol & Exchange: | IMUC OTC:BB | ||
Investor Relations Contact: | Gary Nash | ||
Investor Relations Contact Phone: | 212-732-4300 | ||
Web: | www.imuc.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
IMUC is a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers. The company’s “off the shelf†therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is expected to enter clinical trials early next year. IMUC is in pre-clinical development of a monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. | |||
 | |||
 | |||
Company: | IncrediMail Inc. | ||
Ticker Symbol & Exchange: | NASDAQ:MAIL | ||
Investor Relations Contact: | Jeff Holzmann, President | ||
Investor Relations Contact Phone: | 212.682.1995 | ||
Web: | www.incredimail-corp.com | ||
Date of Presentation: | Sep 11th, 2009 | ||
 | |||
IncrediMailâ„¢ Ltd. (NASDAQ: MAIL) is an internet company founded in 1999 in Tel Aviv, Israel. It designs, markets and delivers high-end personal desktop software. The company's award winning e-mail client product, IncrediMail Premium, is sold in over 100 countries in 10 different languages. Other products include Magentic, a wallpaper and screensaver software for digital personal photos and HiYo, a graphic add-on to instant messaging software. The company went public in January 2006 with an IPO on the US NASDAQ exchange. It currently employs about 110 people in its Tel Aviv and New York offices. In July 2008, IncrediMail signed a contract with Google, making it a partner in Google's "AdSense for Search" program. |
|||
 | |||
 | |||
Company: | InterAmerican Acquisition Group/CNC Dev | ||
Ticker Symbol & Exchange: | OTC BB: IAQG, IAQGW | ||
Investor Relations Contact: | William Morro, CEO | ||
Investor Relations Contact Phone: | Crocker Coulson, CCG, 1(646) 213-1915 | ||
Web: | www.cncdev.com | ||
Date of Presentation: | 10:50AM on Thurs. Sept. 10, 2009 | ||
 | |||
IAG was formed for the purpose of acquiring, through a merger, stock exchange, asset acquisition or other similar business combination, an unidentified operating business. It formed a subsidiary, CNC Development Ltd. for the sole purpose of effecting a redomestication merger and acquiring Sing Kung. Sing Kung Limited (BVI), through its PRC operating subsidiary, forms and leads consortiums to deliver comprehensive city planning and infrastructure build-outs to selected municipalities throughout China. The company’s “Build-Transfer†business model allows local governments to overcome financial and project management constraints and to quickly unlock economic development potential and property value. | |||
 | |||
 | |||
Company: | INX Inc. | ||
Ticker Symbol & Exchange: | INXI | ||
Investor Relations Contact: | Monica Kleypas | ||
Investor Relations Contact Phone: | 713-795-2168 | ||
Web: | http://www.inxi.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
INX Inc. provides technology infrastructure solutions for enterprise-class organizations in the United States. Its solutions include network infrastructure solutions, such as network routing and switching, wireless networking, and network security solutions; unified communications solutions, including Internet protocol (IP) network-based voice or telephone solutions, as well as IP network-based video communications solutions; and data center solutions, such as network storage solutions and data center server virtualization solutions. It also provides planning, design, and implementation professional services, as well as managed support services and technology hosting services. The company also offers IP voice and video communications solutions and network storage solutions. |
|||
 | |||
 | |||
Company: | Iteris, Inc. | ||
Ticker Symbol & Exchange: | ITI NYSE Amex | ||
Investor Relations Contact: | Brett Maas | ||
Investor Relations Contact Phone: | 646-536-7331, [email protected] | ||
Web: | www.iteris.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Iteris, Inc. is a leader in the traffic management market focused on the development and application of advanced technologies that reduce traffic congestion, minimize the environmental impact of traffic congestion, and improve the safety of surface transportation systems infrastructure. Combining outdoor image processing, traffic engineering, and information technology, Iteris offers a broad range of Intelligent Transportation Systems and driver safety solutions to customers worldwide. Iteris is headquartered in Santa Ana, California with offices throughout North America, Europe, and Asia. Investors are encouraged to contact us at 888-329-4483, or at www.iteris.com. |
|||
 | |||
 | |||
Company: | Javelin Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | NYSE Amex: JAV | ||
Investor Relations Contact: | Rick Pierce | ||
Investor Relations Contact Phone: | 617-349-4500 | ||
Web: | www.javelinpharmaceuticals.com | ||
Date of Presentation: | September 9, 2009 at 2:50pm | ||
 | |||
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the acute pain management market. The Company has one marketed drug in the UK and three drug candidates in US Phase 3 clinical development. For additional information about Javelin, please visit the Company's website at http://www.javelinpharmaceuticals.com. | |||
 | |||
 | |||
Company: | Jiangbo Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | OTCBB: JGBO | ||
Investor Relations Contact: | Ms. Elsa Sung | ||
Investor Relations Contact Phone: | (954)727-8435 | ||
Web: | www.jiangbopharma.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Jiangbo Pharmaceuticals, Inc. engages in research, development, production, marketing and sales of medicines in P.R. China. The Company is well positioned to benefit from rapidly growing pharmaceutical market in China by its well known brand, experienced management, skilled workforce and extensive distribution network. It has sales representatives located in all major commerce areas across China. The Company currently has 28 products in its product portfolio and its best selling products include Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Baobaole Chewable Tablets, Radix Isatidis Dispersible Tablets and Laiyang Pear Cough Syrup. | |||
 | |||
 | |||
Company: | KaloBios Pharmaceuticals, Inc. | ||
Investor Relations Contact: | Consuelo Alatorre | ||
Investor Relations Contact Phone: | (650) 243-3120 | ||
Web: | www.kalobios.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
KaloBios focuses on novel, first in class, monoclonal antibodies. We recently completed four Phase 1/2 clinical trials with KB002, an anti-GM-CSF antibody, including one in rheumatoid arthritis and another for persistent asthma. We also completed Phase 1 testing for KB003, a Humaneeredâ„¢ version of the KB002 antibody, and plan to move this forward into Phase 2b studies soon. | |||
 | |||
KaloBios also recently completed two Phase 1/2 clinical trials with KB001, an anti-Pseudomonas antibody; one in France for intensive care patients on mechanical ventilators and the other in the US in patients with cystic fibrosis. Data for these two trials is expected 3Q 2009. | |||
 | |||
KaloBios also plans to file an IND for KB004 in 1H2010, an antibody targeted against a novel epitope (EphA3). We plan to test this in hematologic malignancies and solid tumors. | |||
 | |||
 | |||
Company: | Kodiak Oil & Gas Corp | ||
Ticker Symbol & Exchange: | KOG | ||
Investor Relations Contact: | NYSE | ||
Investor Relations Contact Phone: | David Charles 303-757-2510 | ||
Web: | www.kodiakog.com | ||
Date of Presentation: | 09/09/2009 at 11:15 a.m. (EDT) | ||
 | |||
Denver-based Kodiak Oil & Gas is an independent energy exploration and development company focused on exploring, developing and producing oil and natural gas in the Williston and Green River Basins in the U.S. Rocky Mountains. For further information, please visit www.kodiakog.com. The Company's common shares are listed for trading on the NYSE Amex exchange under the symbol: "KOG." | |||
 | |||
 | |||
Company: | Labrador Iron Mines Holdings Limited | ||
Ticker Symbol & Exchange: | LIM: TSX | ||
Investor Relations Contact: | Donna Yoshimatsu | ||
Investor Relations Contact Phone: | 647-728-4119 | ||
Web: | www.labradorironmines.ca | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Labrador Iron Mines Holdings Limited is focused on the development and production of eight direct-shipping (DSO) iron ore deposits located across a 100 km strike length in the Labrador Trough of the Province of Newfoundland and Labrador near Schefferville, Quebec. The Company's properties are part of the historic Schefferville area iron ore district from which over 150 million tons of iron ore was mined by the Iron Ore Company of Canada (IOC) from 1954 to 1982. The Company is on track to be the first to reactivate DSO iron ore production in Labrador commencing in 2010. The project benefits from the significant existing infrastructure including power, water, airport, roads, 565 km of rail and a deep seaport that exports over 20 million tonnes of iron products annually. | |||
 | |||
 | |||
Company: | MannKind Corporation | ||
Ticker Symbol & Exchange: | MNKD | ||
Investor Relations Contact: | Matthew (Matt) Pfeffer | ||
Investor Relations Contact Phone: | Roberta Dey - Conf. Coord 661-775-554 | ||
Web: | www.mannkindcorp.com | ||
Date of Presentation: | September 10 at 11:40am Eastern | ||
 | |||
MannKind Corporation focuses on the development of therapeutic products for patients with diseases such as diabetes and cancer. We recently submitted an application to the FDA requesting approval of AFRESA® Inhalation Powder for the treatment of adults with type 1 or type 2 diabetes mellitus. | |||
 | |||
AFRESA is an ultra rapid acting insulin with a unique pharmacokinetic profile. AFRESA immediately dissolves upon contact with the lung, releasing insulin monomers that rapidly enter the bloodstream. AFRESA achieves peak insulin levels within 12-14 minutes, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent or impaired in diabetics. | |||
 | |||
 | |||
Company: | MEDIS TECHNOLOGIES LTD. | ||
Ticker Symbol & Exchange: | OTC: MDTL.PK | ||
Investor Relations Contact: | Michael Mason | ||
Investor Relations Contact Phone: | 212.691.8087 | ||
Web: | www.medistechnologies.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Medis, headquartered in New York City, is the first company in the world to design, develop and market a portable liquid fuel cell capable of providing electrical power to mobile electronics. Medis is the only portable fuel cell ever manufactured in commercial quantity with 150,000 working units produced to date. | |||
 | |||
Medis has an impressive IP portfolio, and dedicates considerable resources to maintaining and protecting its rights. The company has several international patents, including patents in Russia. | |||
 | |||
Medis is targeting consumer markets, US and international military markets, and US departments and agencies including FEMA, Border Patrol and Coast Guard. | |||
 | |||
Medis is committed to the environment and green technology – its Power Pack does not contain or use environmentally damaging materials or chemicals and is completely recyclable. | |||
 | |||
 | |||
Company: | Medusa Mining Limited | ||
Ticker Symbol & Exchange: | MML (ASX and AIM) | ||
Investor Relations Contact: | Geoff Davis | ||
Investor Relations Contact Phone: | +618 9367 0601 | ||
Web: | www.medusamining.com.au | ||
Date of Presentation: | 09/10/09 | ||
 | |||
•Philippines focused gold producer, no debt, no hedging | |||
 | |||
•Lowest cash cost producer listed on ASX and AIM | |||
 | |||
•Sixth largest gold producer by market cap on ASX | |||
 | |||
•Long term cash costs US$200/oz | |||
 | |||
•2009-2010 FY production 47,869ozs at US$213/oz cash cost | |||
 | |||
•Total resources 2.03Mozs | |||
- Co-O Mine 1.38Mozs at 10.8g/t gold and expanding | |||
- Bananghilig Deposit 650,000ozs at 1.3g/t gold and open | |||
 | |||
•Co-O Mine reserve 500,000ozs at 14.9g/t gold | |||
 | |||
•On schedule for 100,000ozs annualized production Q1 07/02/05 | |||
 | |||
•Multiple deposit discovery potential in 880km² | |||
- Additional vein deposits | |||
- Additional disseminated gold deposits | |||
- Copper deposits - drilling underway at Lingig with good initial results | |||
 | |||
 | |||
Company: | Midnight Oil Exploration Ltd. | ||
Ticker Symbol & Exchange: | MOX - TSX | ||
Investor Relations Contact: | Jo Ellen Krchnak | ||
Investor Relations Contact Phone: | 403-303-8510 | ||
Web: | www.midnightoil.ca | ||
Date of Presentation: | September 9, 2009 at 2:00pm ET | ||
 | |||
Midnight Oil Exploration Ltd. is a junior-sized energy company with a strong technical team and an excellent asset base comprising the high potential resource play in the Deep Basin of Alberta and a high value light oil production base at Red Earth. We hold over 100 sections in our Deep Basin resource play focused on the multi-layered tight gas potential of the Cadomin and Nikanassin stacked with the high impact conventional gas reservoirs. Our light oil production provides a solid cash flow to capitalize our Deep Basin drilling. We have a proven track record and it is our experience, expertise, innovative operational and business skills, solid balance sheet, light oil production and tremendous resource play prospect inventory that positions Midnight well for the future, contributing strong economics and low risk repeatability. | |||
 | |||
 | |||
Company: | MINEFINDERS CORPORATION LTD | ||
Ticker Symbol & Exchange: | NYSE AMEX:MFNTSX:MFL | ||
Investor Relations Contact: | Mike Wills | ||
Investor Relations Contact Phone: | (604)- 687-6263 | ||
Web: | www.minefinders.com | ||
Date of Presentation: | Thursday 10 Sept. @ 2:50 - 3:15pm | ||
 | |||
Minefinders is a precious metals mining and exploration company. The Company's flagship Dolores Mine in Mexico commenced production of gold and silver in November, 2008 and is expected to produce more than 1.7 million ounces of gold and 64.4 million ounces of silver from heap-leach operations over a 15.5 year mine life. | |||
 | |||
Minefinders Corporation also has property interests in Northern Sonora, including the La Bolsa deposit, the Real Viejo silver prospect, and the Planchas de Plata prospect. The company is headquartered in Vancouver, Canada. | |||
 | |||
 | |||
Company: | Minnow Medical | ||
Investor Relations Contact: | Keith Lippert | ||
Investor Relations Contact Phone: | Lippert Heilshorn & Associates 8383777 | ||
Web: | www.minnowmedical.com | ||
Date of Presentation: | 09/10/09 | ||
Minnow Medical is developing proprietary products to treat artery disease which can occur throughout the body, including the heart, neck, head and lungs. The Company is initially targeting Peripheral Artery Disease, a highly prevalent form of cardiovascular disease found mostly in the lower extremities or legs that impacts 27 million people in North America and Europe. The Company has developed a patent-pending disposable catheter therapy that precisely treats only the atherosclerotic plaque present within an artery. On April 15, 2009, Minnow Medical announced it had received the CE Mark clearing its disposable catheter for marketing in the European Union. | |||
 | |||
 | |||
Company: | Mission New Energy | ||
Ticker Symbol & Exchange: | MBT (ASX) | ||
Investor Relations Contact: | Jennifer K.Zimmons, Ph.D. | ||
Investor Relations Contact Phone: | 212-838-1444 | ||
Web: | www.missionnewenergy.com | ||
Date of Presentation: | Sept 10, 2009 - 10:50am-11:15am | ||
 | |||
Mission NewEnergy Limited is a global renewable energy provider with operations in Australia, Malaysia, India and Mauritius. Biodiesel refineries are located at Kuantan Port in Malaysia. Currently operating a 100,000 tonne per annum biodeisel facility, Mission's second refinery, adjacent to the first facility, will be completed early 2009 providing for a combined capacity of 350,000 tonnes of biodeisel per annum. Mission has a well-developed upstream feedstock business in India, focused on the use of Jatropha Curcas, a non-food, drought resistent crop. The Company's wind power business provides electricity to the state utility of India. | |||
 | |||
 | |||
Company: | MTI MicroFuel Cells, Inc. | ||
Ticker Symbol & Exchange: | MKTY | ||
Investor Relations Contact: | Scott Estro | ||
Investor Relations Contact Phone: | (415) 233 6814 | ||
Web: | www.mtimicrofuelcells.com | ||
Date of Presentation: | Sept. 09, 2009 | ||
 | |||
MTI MicroFuel Cells Inc., a subsidiary of Mechanical Technology, Inc. (OTC:MKTY) is commercializing the Mobion® micro fuel cell in 2010. An off-the-grid mobile power source that uses a “green†renewable fuel called methanol. To penetrate the $70B worldwide battery market, the company has signed agreements with 6 global OEM partners that include Samsung Electronics and a LOI with Duracell. Mobion® technology is also protected by 110 patent applications with 52 granted. Mobion® has a flexible architecture suited for various consumer, industrial, and military markets. The company was recently awarded $2.4 million by US DOE to accelerate micro fuel cell deployment. | |||
 | |||
 | |||
Company: | Nanostart AG | ||
Ticker Symbol & Exchange: | NNS.GR | ||
Investor Relations Contact: | Vanessa Mieschke | ||
Investor Relations Contact Phone: | 0049 69 21 93 96 116 | ||
Web: | www.nanostart.de | ||
Date of Presentation: | 09.08.2009 | ||
 | |||
Nanostart, a nanotechnology investment company, announced today that Marco Beckmann, CEO, is scheduled to present at the 2009 Rodman & Renshaw Conference being held in New York. The presentation is scheduled for 2:00 p.m. (EDT) on Wednesday, September 09, 2009 at the New York Palace Hotel. Marco Beckmann will provide an overview on Nanostart and will highlight current developments of the company and its portfolio. The German based Nanostart invests in young, up-and-coming nanotechnology companies throughout the world. These are companies seeking to commercialize highly innovative products or processes mostly in growth markets such as cleantech, life sciences and healthcare. It currently holds 9 companies from the US, Europe and Asia with groundbreaking technologies in its portfolio. | |||
 | |||
 | |||
Company: | NAPCO Security Technologies, Inc. | ||
Ticker Symbol & Exchange: | NASDAQ: NSSC | ||
Investor Relations Contact: | Donald C. Weinberger | ||
Investor Relations Contact Phone: | (212) 370-4500 | ||
Web: | www.napcosecurity.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
NAPCO Security Technologies, Inc. is one of the world's leading manufacturers of technologically advanced electronic security equipment including intrusion and fire alarm systems, access control and door locking systems. The Company consists of NAPCO plus three wholly-owned subsidiaries: Alarm Lock, Continental Instruments, and Marks USA. The products are installed by security professionals worldwide in commercial, industrial, institutional, residential and government applications. NAPCO products have earned a reputation for technical excellence, reliability and innovation, poising the Company for growth in the rapidly expanding electronic security market, a multi-billion dollar market. | |||
 | |||
 | |||
Company: | Neah Power Systems, Inc. | ||
Ticker Symbol & Exchange: | OTCBB: NPWZ | ||
Investor Relations Contact: | Michael Selsman | ||
Investor Relations Contact Phone: | 310-553-5732 [email protected] | ||
Web: | www.neahpower.com | ||
Date of Presentation: | September 11, 2009, 10 am | ||
 | |||
Neah Power Systems, Inc. (NPWZ) is developing long-lasting, efficient and safe power solutions for the commercial, consumer and military portable electronic devices. Neah uses a unique, patented, silicon-based design for its micro fuel cells that enable higher power densities, lower cost and compact form-factors, and can run in aerobic and anaerobic modes. The company is also developing energy storage solutions based on this technology, as well as off-the-grid renewable energy solutions. | |||
 | |||
Previous investors in Neah Power include Intel Capital, Novellus Systems, and other leading VC firms. The company has also won various accolades and federal grants. | |||
 | |||
 | |||
Company: | Neptune Marine Services Limited | ||
Ticker Symbol & Exchange: | ASX : NMS | ||
Investor Relations Contact: | Neptune Marine | ||
Investor Relations Contact Phone: | 61 8 9424 1111 | ||
Web: | www.neptunems.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Neptune Marine Services is emerging as one of Australia’s leading providers of integrated solutions to the international oil and gas, marine and renewable energy industries. Neptune’s primary focus is the offshore oil and gas sector where its comprehensive suite of subsea services can be tailored to provide engineered solutions that meet the demanding and diverse requirements of both new ‘greenfield’ and existing inspection, repair and maintenance projects. Headquartered in Perth, Western Australia, Neptune also has international operations spanning Australia, Asia, the United States and United Kingdom. | |||
 | |||
 | |||
Company: | Neurologix, Inc. | ||
Ticker Symbol & Exchange: | NRGX.OB | ||
Investor Relations Contact: | John E. Mordock, Pres. & CEO | ||
Investor Relations Contact Phone: | Marc L. Panoff, CFO, Treas. & Sec. | ||
Web: | www.neurologix.net | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Neurologix, Inc. (NRGX.OB) is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and Central Nervous System (CNS). Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. Current company programs address such conditions as Parkinson's disease, Huntington's disease and epilepsy, all of which are large markets not adequately served by current therapeutic options. | |||
201 592 6451 | |||
 | |||
 | |||
Company: | NeuroSearch A/S | ||
Ticker Symbol & Exchange: | NEUR | ||
Investor Relations Contact: | Hanne Leth Hillman | ||
Investor Relations Contact Phone: | 45 4460 8212 | ||
Web: | www.neurosearch.dk | ||
Date of Presentation: | 09/11/09 | ||
 | |||
The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. The drug pipeline comprises seven clinical (Phase I-III) development programmes: Huntexil™(Pridopidine) for Huntington’s disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias in Parkinson’s disease. |
|||
 | |||
 | |||
Company: | New Generation Biofuels | ||
Ticker Symbol & Exchange: | NASDAQ: NGBF | ||
Investor Relations Contact: | Ed Job, CFA | ||
Investor Relations Contact Phone: | [email protected], (646) 213-1914 | ||
Web: | http://www.newgenerationbiofuels.com/ | ||
Date of Presentation: | 09/11/09 | ||
 | |||
New Generation Biofuels Holdings, Inc. is a renewable fuels provider that is marketing a new class of “second generation†biofuels for use in diesel fuel applications, including power generation, commercial and industrial processing, heating and marine transportation. | |||
 | |||
The company produces biofuels using a proprietary blending technology that is less expensive than the complex chemical reaction process used to produce traditional biodiesel. This technology provides the flexibility to produce biofuel from multiple feedstocks, including non-edible raw. | |||
 | |||
New Generation Biofuels’ business model calls for the establishment of biofuel production facilities directly and through sublicensing of its technology to qualified licensees. | |||
 | |||
 | |||
Company: | New Gold Inc. | ||
Ticker Symbol & Exchange: | NGD - TSX and NYSE | ||
Investor Relations Contact: | Melanie Hennessey | ||
Investor Relations Contact Phone: | 604-639-0022 | ||
Web: | www.newgold.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
New Gold Inc. is an intermediate gold producer with cash flow positive operating assets in the United States, Mexico and Australia and development projects in Canada and Chile. The company has a solid platform for profitable growth with a strong financial position to fund its growth strategy and a talented management team and Board of Directors who have the experience to continue to execute on New Gold’s vision of becoming a million ounce, low cost gold producer. | |||
 | |||
 | |||
Company: | Nido Petroleum Limited | ||
Investor Relations Contact: | Dominique Schelfhout | ||
Investor Relations Contact Phone: | 61 8 9474 0000 | ||
Date of Presentation: | Friday 11th September 2009 | ||
 | |||
Nido Petroleum Ltd (ASX:NDO) is an ASX-listed oil and gas exploration and production company focused on Southeast Asia. Its asset base comprises the largest contiguous exploration footprint (about 3 million hectares) in offshore northwest Palawan, the most prolific basin in Philippines which contains the giant Malampaya gas field. | |||
 | |||
Nido has production (22.8% in Galoc oil field), development (60% in Tindalo and Yakal) and exploration (50% deepwater Palawan) assets. | |||
 | |||
An internationally experienced Board of Directors and Management Teams in Perth and Manila continue to deliver on strategy. The Philippines offers the best fiscal regime for the upstream oil and gas sector in the region. | |||
 | |||
 | |||
Company: | Norton Gold Fields Limited | ||
Ticker Symbol & Exchange: | NGF (Australia) | ||
Investor Relations Contact: | Simon Brodie | ||
Investor Relations Contact Phone: | Simon Brodie 61 (0) 411 558 544 | ||
Web: | www.nortongoldfields.com.au | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Norton Gold Fields is one of the largest Australian gold producers. The Company produces around 150,000 oz/year from its open cut operations at Paddington near Kalgoorlie in Western Australia. Paddington has approximately 1.2mm oz of reserves and over 6mm oz of resources. | |||
 | |||
Paddington's annual output is planned to increase towards 200,000 oz over the next 12 months with the development of the Homestead underground mine, which is now underway. | |||
 | |||
Development of the Company's Mount Morgan Mine Project in Queensland will add 30,000-35,000 oz of annual gold production and has all requisite approvals subject to suitable funding. Mount Morgan can be in production within 12 months. | |||
 | |||
Completion of Homestead and Mount Morgan mines will take total annual gold production to 230,000 - 250,000 oz at a projected cash cost of less than A$650/oz. | |||
 | |||
 | |||
Company: | NovaGold Resources Inc. | ||
Ticker Symbol & Exchange: | NG: NYSE -AMEX & TSX | ||
Investor Relations Contact: | Ariadna Peretz | ||
Investor Relations Contact Phone: | 604-669-6227 ext. 126 | ||
Web: | www.novagold.com | ||
Date of Presentation: | Friday, September 11, 2009 | ||
 | |||
NovaGold Resources Inc. (NYSE-AMEX, TSX: NG) is a growth company focused on gold exploration, development and mining. The Company has one of the largest reserve/resource bases in the world relative to its peers, located entirely in North America. Over the course of 10 years NovaGold has acquired and systematically advanced a portfolio of projects to create shareholder value. NovaGold’s resource base has grown from 500,000 ounces of gold in 1998 to 24 million ounces of P&P and M&I and more than 5 million ounces of Inferred resource. The growth and success comes from NovaGold’s experienced exploration team and its ability to forge collaborative partnerships with Native Alaskan and First Nations groups, local communities, major mining companies and regulators. | |||
 | |||
 | |||
Company: | Novelos Therapeutics, Inc. | ||
Ticker Symbol & Exchange: | NVLT OTCBB | ||
Investor Relations Contact: | Stephen Lichaw | ||
Investor Relations Contact Phone: | 201-240-3200 | ||
Web: | www.novelos.com | ||
Date of Presentation: | November 9, 2009, 4:30pm | ||
 | |||
Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under SPA and Fast Track, acts together with chemotherapy as a chemopotentiator and a chemoprotectant. NOV-002 is also in Phase 2 development for early-stage breast cancer and chemotherapy-resistant ovarian cancer. Novelos has a partnership with Mundipharma to develop and commercialize NOV-002 in Europe and Japan. Novelos’ second compound, NOV-205, acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have been partnered with Lee’s Pharm in China. | |||
 | |||
 | |||
Company: | NPS Pharmaceuticals | ||
Ticker Symbol & Exchange: | NPSP - NASDAQ | ||
Investor Relations Contact: | Susan Mesco | ||
Investor Relations Contact Phone: | 908-450-5516 | ||
Web: | www.npsp.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
NPS Pharmaceuticals (Nasdaq: NPSP) is developing new treatment options for patients with rare gastrointestinal and endocrine disorders with clear unmet medical needs. The company is currently conducting two Phase 3 registration studies. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEXâ„¢ in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and in preclinical development for gastrointestinal mucositis and other pediatric indications. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates. | |||
 | |||
 | |||
Company: | Ocean Power Technologies, Inc. | ||
Ticker Symbol & Exchange: | OPTT | ||
Investor Relations Contact: | Charles F. Dunleavy | ||
Investor Relations Contact Phone: | 609-730-0400 | ||
Web: | www.oceanpowertechnologies.com | ||
Date of Presentation: | 07/10/09 | ||
 | |||
Ocean Power Technologies is a pioneer in wave energy technology, with in-ocean experience over 10 years. The Company's proprietary PowerBuoy® system is based on modular, ocean-going buoys that capture and convert predictable wave energy into low-cost, clean electricity. The high value added “smart part†of the system enables the systems to automatically tune their performance to changing wave conditions. The Company’s fundamental business plan is to sell turn-key power stations, plus operating and maintenance service contracts over the life-cycle of the plants. Current customers include the US Navy, Iberdrola SA, the Scottish Government, US DoE and PNGC Power. | |||
 | |||
 | |||
Company: | OctoPlus N.V. | ||
Ticker Symbol & Exchange: | OCTO (Amsterdam) | ||
Investor Relations Contact: | Ms. Rianne Roukema | ||
Investor Relations Contact Phone: | 31-71-5241071 | ||
Web: | www.octoplus.nl | ||
Date of Presentation: | |||
 | |||
OctoPlus is a drug product development company that is globally renowned as a center of excellence in pharmaceutical development and drug delivery. We offer proven and reliable services in formulation development, analytical development, process development and GMP manufacturing. Our expertise is focused on formulation of biotech-derived compounds and small chemical molecules. In addition, we offer clients our expertise in combination with our drug delivery technologies for the development of controlled release formulations of injectable compounds. Such depot formulation products have demonstrated strong improvement of side effect profiles, greatly increased patient compliance and better efficacy. | |||
 | |||
 | |||
Company: | On Track Innovations LTD | ||
Ticker Symbol & Exchange: | NASDAQ GM: OTIV | ||
Investor Relations Contact: | Galit Mendelson/ Miri Segal | ||
Investor Relations Contact Phone: | 1-201-944-5200/1-917-607-8654 | ||
Web: | www.otiglobal.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
On Track Innovations Ltd. (OTI), established in 1990, is a global leader in contactless smart card solutions for homeland security, payments, electronic passports, national IDs, petroleum payments and other applications. OTI’s technology offers commercially available, field-proven,contactless solutions, based on OTI’s significant patents and intellectual property covering the entire value chain. OTI delivers cards, readers, operating systems and complete solutions that are scaleable, offering high functionality, security and flexibility. The Company generates diversified revenue mix from products, services, licensing and transaction fees and has blue chip client base. | |||
 | |||
 | |||
Company: | OncoGenex Pharmaceuticals | ||
Ticker Symbol & Exchange: | OGXI | ||
Investor Relations Contact: | Jason Spark | ||
Investor Relations Contact Phone: | (619) 849-6005 | ||
Web: | www.oncogenex.com | ||
Date of Presentation: | September 10, 2009 at 12:30 p.m. ET | ||
 | |||
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. | |||
 | |||
 | |||
Company: | Oncolytics Biotech Inc. | ||
Ticker Symbol & Exchange: | TSX:ONC, NASDAQ:ONCY | ||
Investor Relations Contact: | Cathy Ward | ||
Investor Relations Contact Phone: | 403.670.7370 | ||
Web: | www.oncolyticsbiotech.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Oncolytics Biotech® Inc. is conducting clinical trials in the U.S. and the U.K. with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program includes seven Phase I/II or Phase II human trials examining REOLYSIN alone or in combination with chemotherapy. | |||
 | |||
This clinical program is designed to identify targets for late-stage registration trials with REOLYSIN, the first of which is planned to be a Phase III combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers. |
|||
 | |||
 | |||
Company: | Oramed Pharmaceuticals | ||
Ticker Symbol & Exchange: | OTC: ORMP | ||
Investor Relations Contact: | Tara Horn | ||
Investor Relations Contact Phone: | 1-646-240-4193 | ||
Web: | www.oramed.com | ||
Date of Presentation: | Friday September 11, 2009 | ||
 | |||
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.Oramed's pipeline currently consists of an insulin suppository (ORMD-0802) and an oral method for delivery of GLP1 analog (ORMD-0901) and the influenza vaccine (ORMD-1001). Oramed's unique oral delivery technology serves as a platform for other vaccines and medications currently available exclusively in injection. | |||
 | |||
 | |||
Company: | Orexo | ||
Ticker Symbol & Exchange: | STO: ORX | ||
Investor Relations Contact: | Johan Andersson | ||
Investor Relations Contact Phone: | 46 702 100 451 | ||
Web: | www.orexo.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Orexo is a Swedish pharmaceutical company with a focus on the therapeutic areas of pain and inflammation. Orexo’s first proprietary developed drug, Abstral, for the treatment of breakthrough pain in cancer patients was launched in Europe in 2008. The second drug, Edluar - for the short-term treatment of insomnia was recently launched in the USA. Orexo has a number of projects in the pipeline and also markets two diagnostic products for the gastric ulcer bacteria, Helicobacter pylori, through its Kibion subsidiary. | |||
 | |||
 | |||
Company: | Orient Paper Inc. | ||
Ticker Symbol & Exchange: | OTC BB: OPAI | ||
Investor Relations Contact: | Winston Yen, CFO | ||
Investor Relations Contact Phone: | Crocker Coulson, CCG, 1(646) 213-1915 | ||
Web: | www.orientalpapercorporation.com | ||
Date of Presentation: | 5:45PM on Thurs, Sept. 10, 2009 | ||
 | |||
Orient Paper, Inc., through its wholly owned subsidiaries, Shengde Holdings, Inc. and Baoding Shengde Paper Co., Ltd., controls and operates Hebei Baoding Orient Paper Milling Co., Ltd ("HBOP"). Founded in 1996, HBOP is engaged in the production and distribution of products such as printing paper, uncoated and coated paper, corrugated paper, plastic paper, graphic design paper, and other paper and packaging-related products in China. The Company uses recycled paper as its primary raw material. As one of the largest paper producers in Hebei Province, China, the Company is strategically located in Baoding, a city in close proximity to Beijing where the majority of publishing houses are based. Orient Paper is committed to diversifying the Company's product offering and delivering tailored services to its customers. | |||
 | |||
 | |||
Company: | Osteologix, Inc. | ||
Ticker Symbol & Exchange: | OLGX: OTCBB | ||
Investor Relations Contact: | Baxter Phillips, III | ||
Investor Relations Contact Phone: | 804-747-6026 | ||
Web: | www.osteologix.com | ||
Date of Presentation: | Wednesday, September 9, 2009 | ||
 | |||
Osteologix is a specialty biopharmaceutical company committed to improving the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead investigational product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com. | |||
 | |||
 | |||
Company: | Oxygen Biotherapeutics, Inc. | ||
Ticker Symbol & Exchange: | OXBO OTCBB | ||
Investor Relations Contact: | Abe Wischnia | ||
Investor Relations Contact Phone: | 619-795-2345 | ||
Web: | www.oxybiomed.com | ||
Date of Presentation: | Sept. 9, 2009 | ||
 | |||
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine™. The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte®) and has out-licensed an implantable glucose sensor. Core technologies include biomedical applications for PFCs and medical and industrial applications for biosensors. Each product candidate is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. | |||
 | |||
 | |||
Company: | Pacific Asia Petroleum, Inc. | ||
Ticker Symbol & Exchange: | PFAP | ||
Investor Relations Contact: | John Liviakis / Michael Bayes | ||
Investor Relations Contact Phone: | 415-389-4670 | ||
Web: | www.papetroleum.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Pacific Asia Petroleum is an energy company focused on low-risk, high-return development and production stage opportunities. The Company is primarily engaged in the business of oil and gas development, production and distribution in Pacific Rim countries, with an initial focus on China. It is a strategic partner with several major energy companies in high-value oil and gas fields in China. It was founded in 2005 by a group of senior Texaco executives and is led by CEO Frank Ingriselli. Pacific Asia is a publicly traded US headquartered company with executive offices in New York and offices in Beijing and California. |
|||
 | |||
 | |||
Company: | PAION AG | ||
Ticker Symbol & Exchange: | PA8 | ||
Investor Relations Contact: | Ralf Penner | ||
Investor Relations Contact Phone: | 49-2414453152 | ||
Web: | www.paion.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals, which was completed in June 2008, the company has a second site in Cambridge, UK.The company is specializing in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.PAION intends further expand its portfolio of drugs by exploiting its core expertise in identifying high-potential compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process.PAION is listed at the Frankfurt Stock Exchange (Prime Standard Regulated Market, Stock Symbol PA8, ISIN DE000A0B65S3). | |||
 | |||
 | |||
Company: | Perma-Fix Environmental Services | ||
Ticker Symbol & Exchange: | PESI: Nasdaq | ||
Investor Relations Contact: | David Waldman | ||
Investor Relations Contact Phone: | 212-671-1020 | ||
Web: | www.perma-fix.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Perma-Fix Environmental Services, Inc., a national environmental services company, provides unique mixed waste and industrial waste management services. The Company’s increased focus on nuclear services includes radioactive and mixed waste treatment services for hospitals, research labs and institutions, federal agencies, including DOE, DOD, and nuclear utilities. The Company’s industrial services treat hazardous and non-hazardous waste for a variety of customers including, Fortune 500 companies, federal, state and local agencies and thousands of other clients. Nationwide, the company operates seven waste treatment facilities. | |||
 | |||
 | |||
Company: | Pluristem Therapeutics Inc. | ||
Ticker Symbol & Exchange: | PSTI | ||
Investor Relations Contact: | William R. Prather RPh, MD | ||
Investor Relations Contact Phone: | 303-883-4954 | ||
Web: | www.pluristem.com | ||
Date of Presentation: | September 10th 2009 | ||
 | |||
Pluristem Therapeutics Inc. is a clinical development bio-therapeutics company dedicated to the commercialization of unrelated donor-patient placenta-derived stem cell products to treat disorders with an unmet medical need. | |||
 | |||
Pluristem initiated Phase I studies in the U.S. and Germany utilizing Pluristem's first product, PLX-PAD, for the treatment of peripheral artery disease (PAD), and has received approvals from both the U.S. Food & Drug Administration (FDA) and the Paul Ehrlich Institute (PEI), Germany’s competent authority. | |||
 | |||
The company derives its product pipeline from human placentas, which possess the advantage of being readily available. The PLacental eXpanded cell products (PLX) are stored off-the-shelf, ready-to-use, and require no histocompatibility matching. | |||
 | |||
 </td> | |||
Company: | Poniard Pharmaceuticals | ||
Ticker Symbol & Exchange: | PARD NASDAQ | ||
Investor Relations Contact: | Susan Neath | ||
Investor Relations Contact Phone: | 212-213-0006 | ||
Web: | www.poniard.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. | |||
 | |||
 | |||
Company: | Power Efficiency Corporation | ||
Ticker Symbol & Exchange: | PEFF on OTCBB | ||
Investor Relations Contact: | BJ Lackland, CFO | ||
Investor Relations Contact Phone: | 702-697-0377 x103 | ||
Web: | www.powerefficiency.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Power Efficiency Corporation is a clean tech company focused on energy efficiency technologies for electric motors. The Company has developed a patented technology platform, called E-Save Technology, that has been demonstrated in independent testing to improve the efficiency of electric motors by up to 35% in appropriate applications. According to the Department of Energy, electric motors are the largest end users of electricity in the U.S. and many operate inefficiently. Power Efficiency’s products include a Motor Efficiency Controller for applications such as escalators, crushers, granulators, and saws, and a new Appliance Controller for washers, dryers and other appliances. The Company has OEM agreements with major elevator/escalator companies and has completed projects at numerous airports, malls, and industrial facilities. | |||
 | |||
 | |||
Company: | Protox Therapeutics | ||
Ticker Symbol & Exchange: | TSX: PRX | ||
Investor Relations Contact: | Michael Moore | ||
Investor Relations Contact Phone: | 416-815-0700 x241 | ||
Web: | www.protoxtherapeutics.com | ||
Date of Presentation: | Thursday, September 10, 2009 | ||
 | |||
Protox Therapeutics is a leader in advancing novel, receptor targeted fusion proteins. Lead program, PRX302, is currently being studied in a Phase 2b placebo controlled trial to treat benign prostatic hyperplasia (BPH or enlarged prostate). Final positive Phase 2a results treating BPH patients were released at the end of 2008, with 12 month follow-up data coming in September 2009. A Phase 2a clinical trial evaluating PRX321 for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA and EMEA. | |||
 | |||
 | |||
Company: | Provectus Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | OTC BB: PVCT | ||
Investor Relations Contact: | Peter R. Culpepper | ||
Investor Relations Contact Phone: | 866-594-5999 Ext. 30 | ||
Web: | www.pvct.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and liver metastases. The Company has orphan drug designation from the FDA for its melanoma indication. Its dermatological drugs also target abnormal or diseased cells, with the focus on psoriasis and atopic dermatitis. Provectus completed enrollment in two of its Phase 2 trials -- PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for atopic dermatitis. | |||
 | |||
 | |||
Company: | pSivida Corp. | ||
Ticker Symbol & Exchange: | PSDV - NASDAQ | ||
Investor Relations Contact: | Bev Jedynak | ||
Investor Relations Contact Phone: | 312-943-1123 | ||
Web: | www.psivida.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
pSivida, a leading provider of miniaturized sustained-release drug delivery systems, is developing products designed to revolutionize treatments in critical areas such as ophthalmology, oncology and cardiology. | |||
 | |||
The company already has two FDA approved products on the market and a third (Iluvienâ„¢) in Phase III clinical trials for Diabetic Macular Edema, a leading cause of blindness and an unserved billion dollar plus potential market. pSivida anticipates receiving top line 24 month interim data this year which will form the basis for an NDA filing with the FDA planned for early 2010. | |||
 | |||
pSivida has partnerships with Pfizer, Baush & Lomb and Alimera Sciences. | |||
 | |||
 | |||
Company: | Quantum Immunologics, Inc. | ||
Investor Relations Contact: | Mr. Tim Schwiers | ||
Investor Relations Contact Phone: | 813-849-7859 | ||
Web: | www.quantumimmunologics.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Quantum Immunologics is a privately held company that is dedicated to the research, development and production of products and services that will promote unique, individualized immunologic cancer treatment and early detection technologies with a high rate of efficacy, minimal side effects and greatly reduced cost compared to current treatments. | |||
 | |||
Quantum Immunologics has received FDA authorization to apply its exclusively-licensed patented immunotherapy in a Phase I/II human clinical study. The clinical trial, which involves a cohort of twenty seven (27) patients with advanced stage IV breast cancer, is currently underway. | |||
 | |||
 | |||
Company: | Redpoint Bio Corporation | ||
Ticker Symbol & Exchange: | RPBC (OTC:BB) | ||
Investor Relations Contact: | Scott M. Horvitz, CFO | ||
Investor Relations Contact Phone: | 609-637-9700 | ||
Web: | www.redpointbio.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Redpoint’s understanding of the biology of taste and its relationship to metabolism, satiety, and diabetes impact both the development of healthier foods and potentially, new approaches for treating diabetes and obesity. Redpoint is developing taste modulators for the food and beverage industry with the aim of enhancing sweet and savory flavors in food and beverage products which can lead to reductions in added sugar and salt. The development of healthier and more tasteful food can contribute to improving the overall health of the world’s population, since many modern diseases are related to excess dietary sugar and salt. |
|||
 | |||
 | |||
Company: | Regado Biosciences, Inc. | ||
Investor Relations Contact: | David J. Mazzo, Ph.D. | ||
Investor Relations Contact Phone: | 908 580 2111 | ||
Web: | www.regadobio.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado’s technology is designed to give physicians the ability to actively and directly control each system’s therapeutic effect providing a safe and unique approach to personalized medicine. | |||
 | |||
 | |||
Company: | RegeneRx Biopharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | RGN NYSE: Amex | ||
Investor Relations Contact: | J.J. Finkelstein | ||
Investor Relations Contact Phone: | 301-280-1992 | ||
Web: | www.regenerx.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company whose primary focus is the research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. | |||
 | |||
RegeneRx is currently moving three drug candidates through the clinic: RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic and cardiovascular wound healing, respectively. RegeneRx is also developing novel peptides for cosmeceutical applications, separate and distinct from its pharmaceutical products, and is currently pursuing strategic marketing relationships for these products. The Company holds over 60 issued patents and patent applications worldwide. | |||
 | |||
 | |||
Company: | Renasant Corporation | ||
Ticker Symbol & Exchange: | RNST | ||
Investor Relations Contact: | John Oxford | ||
Investor Relations Contact Phone: | 662-680-1219 and [email protected] | ||
Web: | www.renasant.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Renasant Corporation is the parent of Renasant Bank and Renasant Insurance. Renasant has assets of approximately $3.70 billion and operates over 60 banking, mortgage, insurance and financial services offices in Mississippi, Tennessee and Alabama. | |||
 | |||
 | |||
Company: | Republic Bancorp, Inc. | ||
Ticker Symbol & Exchange: | NASDAQ - RBCAA | ||
Investor Relations Contact: | Kevin Sipes, EVP & CFO | ||
Investor Relations Contact Phone: | (502) 584-3600 ext. 8628 | ||
Web: | www.republicbank.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Republic Bancorp, Inc. (Republic) has 44 banking centers and is the parent company of: Republic Bank & Trust Company with 35 banking centers in 13 Kentucky communities and three banking centers in southern Indiana. Republic Bank has five banking centers in the Greater Tampa area of Florida as well as one banking center in Cincinnati, Ohio. | |||
 | |||
Republic operates Tax Refund Solutions, a nationwide tax refund loan and check provider. Republic offers internet banking at www.republicbank.com. Republic has $3.1 billion in assets and $1 billion in trust assets under custody and management. Republic is headquartered in Louisville, Kentucky, and Republic's Class A Common Stock is listed under the symbol 'RBCAA' on the NASDAQ Global Select Market. | |||
 | |||
We were here for you yesterday. We are here for you today. We will be here for you tomorrow. ® | |||
 | |||
 | |||
Company: | Result Energy Inc. | ||
Ticker Symbol & Exchange: | RTE | ||
Investor Relations Contact: | William Matheson | ||
Investor Relations Contact Phone: | 403.777.0007 | ||
Web: | www.resultenergy.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Result Energy Inc. (“Resultâ€) is a junior, publicly traded (RTE-X) Oil & Gas exploration and production company which is headquartered in Calgary. Result’s current strategy is to expand operations through a combination of internally developed prospects and strategic acquisitions. Up until recently, Result Energy was a conventional natural gas producer in Saskatchewan and Alberta. Now Result Energy has a significant undeveloped land position in the emerging Horn River BC shale gas play in North-East BC. The Current concentration is with Joint Venture partners at the high prospective Horn River basin in BC. Result is partnered with a large energy trust in 43 gross (26 net) sections at Gunnell Creek, and with a private company in 25 gross (2.5 net) sections at Dilly Creek. | |||
 | |||
 | |||
Company: | Resverlogix Corp. | ||
Ticker Symbol & Exchange: | TSX:RVX | ||
Investor Relations Contact: | Theresa Kennedy | ||
Investor Relations Contact Phone: | |||
Web: | www.resverlogix.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Resverlogix is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ PR program is the Company’s primary focus which is to develop novel small molecules that enhance ApoA-1/HDL. These vital therapies address the grievous burden of atherosclerosis. RVX-208, the lead novel small molecule, is just completing a Phase 1b/2a clinical trial. RVX-208 is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To date RVX-208 is the only small molecule that is designed to increase ApoA-I production and raise HDL levels. | |||
 | |||
 | |||
Company: | Rodobo International, Inc | ||
Ticker Symbol & Exchange: | OTCBB: RDBO | ||
Investor Relations Contact: | Rita Jiang/ Miri Segal Scharia | ||
Investor Relations Contact Phone: | 1-646-691-5047/ 1-917-607-8654 | ||
Web: | www.rodobo.com.cn | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Rodobo International, Inc. is engaged in producing, R&D, marketing and distributing high-quality milk formula products in China. | |||
 | |||
The Company offers 3 product lines, 16 different products targeting infants, children, middle aged and elderly. Products are sold under “Rodoboâ€, “Peerâ€, Healif†brands through 126 distributors to 4,463 retail stores in 6 provinces. Rodobo is strategically located in Heilongjiang province which is recognized as one of the world’s best area for dairy cow farming. In 2008, Rodobo International was honored "Best Quality Control Enterprise of Dairy Productsâ€. | |||
 | |||
 | |||
Company: | S.Y. Bancorp | ||
Ticker Symbol & Exchange: | SYBT: NASDAQ GS | ||
Investor Relations Contact: | Nancy B. Davis, CFO | ||
Investor Relations Contact Phone: | 502-625-9176 | ||
Web: | www.syb.com | ||
Date of Presentation: | Wednesday, September 9, 2009 | ||
 | |||
S. Y. Bancorp, Inc., with $1.7 billion in assets, was incorporated in 1988 as a bank holding company. It is the parent company of Stock Yards Bank & Trust Company, which was established in 1904 in Louisville, Kentucky, and has offices in metropolitan Louisville, Indianapolis and Cincinnati. The Company also offers trust and investment services, with $1.4 billion in assets under management at the end of 2008, which sharply differentiates S.Y. Bancorp from many competitors. S.Y Bancorp's common shares trade on the NASDAQ Global Select Market under the symbol SYBT. | |||
 | |||
 | |||
Company: | SciClone Pharmaceuticals | ||
Ticker Symbol & Exchange: | SCLN | ||
Investor Relations Contact: | Ana Kapor | ||
Investor Relations Contact Phone: | 650.358.3437 | ||
Web: | www.sciclone.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
SciClone Pharmaceuticals is a profit-driven, global biopharmaceutical company with a substantial international business and a product portfolio for cancer and infectious diseases. ZADAXIN is sold for the treatment of hepatitis B and C , certain cancers and as a vaccine adjuvant. SciClone's pipeline includes thymalfasin for stage IV melanoma,; RP101 in phase 2 for the treatment of pancreatic cancer; SCV-07 in phase 2 for oral mucositis ; SCV-07 with a ready-to-initiate phase 2 trial for hepatitis c. SciClone has exclusive commercialization rights and is seeking regulatory approval for DC Bead in China, and to ondansetron RapidFilm in China and Vietnam. | |||
 | |||
 | |||
Company: | Sharps Compliance Corp. | ||
Ticker Symbol & Exchange: | SMED:NASDAQ | ||
Investor Relations Contact: | Craig Mychajluk | ||
Investor Relations Contact Phone: | 716-843-3832 | ||
Web: | www.sharpsinc.com | ||
Date of Presentation: | 09.10.2009 | ||
 | |||
Sharps Compliance (NASDAQ:SMED) is a leading provider of cost-effective disposal solutions for medical and pharmaceutical waste generated outside the hospital setting. The Sharps®MWMS™, a Medical Waste Management System, includes the Sharps Disposal By Mail System® and an array of other services and products necessary to effectively collect, store and dispose of medical waste outside of the hospital setting; is designed for rapid deployment and to be an integral part of governmental and commercial emergency preparedness programs. Sharps Compliance is a fully integrated manufacturer and markets its products to the pharmaceutical, government, healthcare, retail, agriculture, commercial, industrial, hospitality, professional, and residential markets. | |||
 | |||
 | |||
Company: | ShengdaTech, Inc. | ||
Ticker Symbol & Exchange: | SDTH | ||
Investor Relations Contact: | Crocker Coulson | ||
Investor Relations Contact Phone: | 646 213 1915 | ||
Web: | http://www.shengdatechinc.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
ShengdaTech, Inc. (“ShengdaTech†or “the Companyâ€) is a leading manufacturer of nano-precipitated calcium carbonate (“NPCCâ€) in the high-tech chemical manufacturing industry. The Company is engaged in developing, producing, marketing, and globally distributing a broad range of NPCC products that enhance the value of everyday products. ShengdaTech’s flagship NPCC product is comprised of microscopic nano particles with unique chemical and physical attributes, which serve as a filler and function as a performance-enhancing ingredient to improve significantly the quality of end products. ShengdaTech is China’s largest NPCC manufacturer in terms of production capacity and revenue. The Company currently operates three NPCC manufacturing facilities with current total annual NPCC manufacturing capacity of 250,000 metric tons. | |||
 | |||
 | |||
Company: | Sinapis Pharma | ||
Investor Relations Contact: | Dr Donald Picker | ||
Investor Relations Contact Phone: | 862 273-1432 | ||
Web: | www.sinapispharma.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
SINAPIS PHARMA INVESTMENT CONSIDERATIONS |
|||
 |
|||
•Strong data in accepted models of stroke repeated in two laboratories | |||
 | |||
•New blockbuster indication ( stroke ) for a novel route of administration of an FDA approved drug | |||
 | |||
•FIRST DRUG TO EXHIBIT NEUROPROTECTION IN ANIMAL MODELS AT 12 HOURS AFTER STROKE | |||
 | |||
•Rapid and inexpensive development pathway to proof of principle in man | |||
 | |||
•Safety established from previous extensive use in man | |||
 | |||
•GMP manufacturing and related drug issues resolved | |||
 | |||
•Several other clinical indications in development (TRAUMATIC BRAIN INJURY) | |||
 | |||
•Renowned scientific and clinical stroke advisory board | |||
 | |||
•Highly experienced and successful development team | |||
 | |||
 | |||
Company: | Sino Clean Energy Inc. | ||
Ticker Symbol & Exchange: | OTCBB:SCLX | ||
Investor Relations Contact: | Kevin Fickle | ||
Investor Relations Contact Phone: | 415-332-7200 | ||
Web: | www.sinocei.net | ||
Date of Presentation: | September 10th, 2009, 2:25PM | ||
 | |||
Sino Clean Energy Inc. ("SCLX") is a China-based producer and distributor of Coal Water Mixture ("CWM")--a fuel substitute for oil, gas or coal in industrial, heating and power generation boilers. SCLX is the principal CWM producer in its immediate market in Shaanxi Province. | |||
 | |||
The company reported a revenue of $13.7 million and per share earning of $0.03 in 2008. In the first quater of 2009, SCLX added a Fluid Accoustic Energy System, resulting in a 250% capacity expansion and improved margins. | |||
 | |||
Financing: | |||
In July 2009, the company raised approximately an $11.6 million in gross proceeds in a private financing. | |||
 | |||
 | |||
Company: | SINO GAS INTL. HOLDINGS | ||
Ticker Symbol & Exchange: | OTCBB: SGAS.OB | ||
Investor Relations Contact: | STRATEGIC GROWTH INTERNATIONAL | ||
Investor Relations Contact Phone: | RICHARD COOPER, 212-838-1444 | ||
Web: | www.sino-gas.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Sino Gas International Holdings is one of the fastest-growing natural gas distributors in China. The Company has 37 natural gas distribution networks, with four under construction. Sino Gas distributes natural gas to more than 100,000 residential and several significant industrial customers. Sino Gas has invested over $48M in infrastructure to date, which includes approximately 710km of distribution networks with a daily capacity of approximately 89,000 cubic meters of gas. Business development is focused on small and medium-sized cities throughout China, which are being rapidly urbanized. The distribution systems are in five provinces and Beijing, where Sino Gas is headquartered. | |||
 | |||
 | |||
Company: | SinoHub, Inc. | ||
Ticker Symbol & Exchange: | NYSE Amex: SIHI | ||
Investor Relations Contact: | Laurie Berman, PondelWilkinson | ||
Investor Relations Contact Phone: | 310-279-5962 | ||
Web: | www.sinohub.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
SinoHub has invented a new business model for electronics supply chain management (SCM) in China by creating a platform that makes the entire supply chain transparent for all industry participants. | |||
 | |||
China is the world's largest consumer of electronic components and the largest producer of electronic products. The explosive growth and decentralized nature of the Chinese market, combined with the availability of Web-based technology, has created new prospects for third-party electronic component SCM service providers like SinoHub. With robust solutions for SCM services and procurement-fulfillment for participants in the electronics supply chain, SinoHub is well positioned to capture significant, high growth opportunities in this dynamic market. | |||
 | |||
 | |||
Company: | Small Bone Innovations Inc. | ||
Ticker Symbol & Exchange: | privately owned | ||
Investor Relations Contact: | varun gandhi | ||
Investor Relations Contact Phone: | 212.583.0370 ext 2126 | ||
Web: | www.totalsmallbone.com | ||
Date of Presentation: | 9.17.09 | ||
 | |||
Small Bone Innovations Inc. (SBi) is the only company focused purely on small bone & joint implants and fixation systems used by orthopedic surgeons. Founded in 2004, the company offers more than 60 product systems worldwide. SBi recently launched the clinically proven STAR ankle replacement system in the US after FDA approval in May, 2009. The STAR is the only 3-part, uncemented, mobile bearing total ankle replacement available in the US. Today, SBi has more than 130 employees in the US, France and Germany. | |||
 | |||
 | |||
Company: | Solar Energy Initiatives, Inc | ||
Ticker Symbol & Exchange: | (SNRY) - OTC BB | ||
Investor Relations Contact: | Chris Camarra | ||
Investor Relations Contact Phone: | 212-398-3487 | ||
Web: | www.solarenergy.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Solar Energy Initiatives, Inc. (www.SolarEnergy.com) is executing its “RENEW THE NATION†campaign, intended to promote job growth nationwide via an aggressive grass roots effort. The main focus of RENEW THE NATION will be working with companies in the construction industry and related trades affected by the economic downturn to re-train and re-deploy their workforce, allowing this important national asset to meet the needs of the Solar Energy industry, the fastest growing industry in the world. | |||
 | |||
</td> | Â | ||
Company: | Somaxon Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | SOMX: NASDAQ | ||
Investor Relations Contact: | Rob Whetstone | ||
Investor Relations Contact Phone: | Rob Whetstone, 310-279-5980 | ||
Web: | www.somaxon.com | ||
Date of Presentation: | September 10, 2009 @ 2:25 p.m. | ||
 | |||
Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon’s lead compound is Silenor® (doxepin), for the treatment of insomnia. Somaxon has submitted a New Drug Application for Silenor® to the U.S. Food and Drug Administration. The FDA has accepted the submission for review and the FDA action date is expected to be December 4, 2009. | |||
 | |||
 | |||
Company: | Sonic Foundry | ||
Ticker Symbol & Exchange: | Nasdaq SOFO | ||
Investor Relations Contact: | Rob Schatz, Wolfe Axelrod | ||
Investor Relations Contact Phone: | 212.370.4500 | ||
Web: | www.sonicfoundry.com | ||
Date of Presentation: | 09/09/09 3:15pm Eastern | ||
 | |||
Sonic Foundry (NASDAQ: SOFO, www.sonicfoundry.com), the global leader for rich media webcasting and knowledge management, provides enterprise communication solutions for more than 1,500 customers in education, business and government. Powered by Mediasite, the patented webcasting platform which automates the capture, management, delivery and search of lectures, online training and briefings, Sonic Foundry empowers people to transform the way they communicate. Through the Mediasite platform and its Events Services group, the company helps customers connect a dynamic, evolving world of shared knowledge and envisions a future where learners and workers around the globe use webcasting to bridge time and distance, accelerate research and improve performance. | |||
 | |||
 | |||
Company: | SORL Auto Parts, Inc. | ||
Ticker Symbol & Exchange: | NASDAQ:SORL | ||
Investor Relations Contact: | Ben (Zili) Chen | ||
Investor Relations Contact Phone: | 86-577-65817720 | ||
Web: | http://www.sorl.cn | ||
Date of Presentation: | Sep 9th, 2009 | ||
 | |||
As China's leading manufacturer and distributor of automotive air brake valves, SORL Auto Parts, Inc. ranks first in market share in the segment for commercial vehicles weighing more than three tons, such as trucks and buses. The Company distributes products both within China and internationally under the SORL trademark. SORL ranks among the top 100 auto component suppliers in China, with a product range that includes 40 types of air brake valves and over 1000 different specifications. The Company has four authorized international sales centers in Australia, United Arab Emirates, India, and the United States. | |||
 | |||
 | |||
Company: | Spherix Incorporated | ||
Ticker Symbol & Exchange: | NASDAQ CM/SPEX | ||
Investor Relations Contact: | Matthew Duch | ||
Investor Relations Contact Phone: | 301-897-2564 | ||
Web: | www.spherix.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Spherix Incorporated is a drug and scientific research company with two subsidiaries—Biospherics Incorporated and Spherix Consulting, Inc. | |||
 | |||
Biospherics has patented the use of Naturlose as a safe drug to treat diabetes, and is currently running a Phase 3 clinical trial to study Naturlose as a treatment for Type 2 diabetes. | |||
 | |||
The Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit www.spherix.com. | |||
 | |||
 | |||
Company: | St Andrew Goldfields Ltd. | ||
Ticker Symbol & Exchange: | SAS: TSX | ||
Investor Relations Contact: | Suzette N Ramcharan | ||
Investor Relations Contact Phone: | 416-815-9855 ext. 234 | ||
Web: | www.sasgoldmines.com | ||
Date of Presentation: | Friday September 11, 2009 @ 10:25am | ||
 | |||
St Andrew Goldfields Ltd., (SAS) is a Canadian based gold mining and exploration Company with an extensive land package in the Timmins mining district, Northeastern Ontario, Canada, which lies within the world famous Abitibi greenstone belt. | |||
 | |||
SAS’ initial focus is to return to being a producer through its Holloway Mine, and Hislop Project. With the existing infrastructure in place (two fully constructed underground mines, permits, mill with a 3,000 tpd capacity, access roads, and power) and a dedicated and experienced team, SAS is poised for a return to production by November 2009. In 2010, SAS will commence an aggressive exploration program on this gold rich region, ensuring future growth opportunities. | |||
 | |||
 | |||
Company: | Steel Vault Corporation | ||
Ticker Symbol & Exchange: | OTCBB: SVUL | ||
Investor Relations Contact: | Allison Tomek | ||
Investor Relations Contact Phone: | 561-805-8044 | ||
Web: | www.steelvaultcorp.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Steel Vault Corporation, through its NationalCreditReport.com subsidiary, offers consumers a variety of identity security products and services primarily on a subscription basis. These services help consumers protect themselves against identity theft or fraud, and understand and monitor their credit profiles and other personal information, which include credit reports, credit monitoring and credit scores. For the quarter ended June 30, 2009, the company reported record revenue, up more than 500% from its previous quarter, and a rapidly growing subscriber base. | |||
 | |||
 | |||
Company: | Strathmore Minerals Corp | ||
Ticker Symbol & Exchange: | STM.V (TSX Venture) | ||
Investor Relations Contact: | Craig Christy | ||
Investor Relations Contact Phone: | Craig Christy 1-800-647-3303 | ||
Web: | www.strathmoreminerals.com | ||
Date of Presentation: | September 10, 2009, 4:55 PM | ||
 | |||
Strathmore Minerals Corp is a Canadian based resource company specializing in the development of advanced uranium properties in the United States. | |||
 | |||
Strathmore's primary goal is to become a leading uranium producer in the USA. The Company has an extensive and diverse property portfolio, located primarily in Wyoming and New Mexico. In 2009, the Company is continuing to permit its three core uranium development projects: the Gas Hills and Pine-Tree Reno Creek properties in Wyoming, and Roca Honda in New Mexico. Strathmore's management and technical team led by CEO David Miller has over 200 years of uranium exploration and mining experience. | |||
 | |||
 | |||
Company: | Summit State Bank | ||
Ticker Symbol & Exchange: | SSBI | ||
Investor Relations Contact: | Tom Duryea | ||
Investor Relations Contact Phone: | 707-758-5211 | ||
Web: | www.SummitStateBank.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
Headquartered in Sonoma County, the Bank provides diverse financial products and services throughout Sonoma, Napa, San Francisco, and Marin Counties. | |||
 | |||
Company Highlights: | |||
 | |||
• Record earnings in 1st half of 2009 | |||
 | |||
• Highest funding month in bank’s history in Q4 09 | |||
 | |||
• Efficiency ratio improving from 69% at Q1 08 to 55% for 1st half of 2009 | |||
 | |||
• Overall performance has improved from bottom quartile of peer banks at Q1 08 to top quartile at Q1 09 | |||
 | |||
• Sonoma County’s Top Rated Bank by Bauer Financial for five consecutive quarters | |||
 | |||
 | |||
Company: | SuperGen | ||
Ticker Symbol & Exchange: | NASDAQ: SUPG | ||
Investor Relations Contact: | Susanna Chau | ||
Investor Relations Contact Phone: | 925-560-2845 | ||
Web: | www.supergen.com | ||
Date of Presentation: | Sept. 10, 2009 at 11:40 am ET | ||
 | |||
SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. Based in Dublin, California, SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com. | |||
 | |||
 | |||
Company: | tedRedPath Integrated Pathology, Inc. | ||
Web: | www.redpathip.com | ||
Date of Presentation: | September 10, 2009 @3:40 PM | ||
 | |||
RedPath is a commercially proven genomics-based molecular diagnostics laboratory services company. RedPath’s technology uses molecular mutational profiles to resolve indeterminate, incomplete and inaccurate diagnoses to provide guidance for the proper management and treatment of cancer patients. | |||
 | |||
RedPath's business strategy is to provide high quality solutions for diagnostic dilemmas utilizing molecular tools that lead to a more definitive diagnosis and therefore a clear call to action for the treating physician and patient. The PathFinderTG Profile increases flexibility using existing samples and fluids, lowers total cost of care for patients, providers & payors. The marketing strategy is to provide services directly to clinicians and laboratories with a direct sales force. Results have been promising with over 6,000 specimens tested. | |||
 | |||
 | |||
Company: | Thorium Power, Ltd. | ||
Ticker Symbol & Exchange: | THPW: OTCBB | ||
Investor Relations Contact: | Peter Charles | ||
Investor Relations Contact Phone: | 571-730-1213 | ||
Web: | www.thoriumpower.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Thorium Power is a pioneering U.S. nuclear energy company based in McLean, VA. The Company develops non-proliferative nuclear fuel technology and provides comprehensive advisory services for emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. The Company maintains a seasoned team with unparalleled experience from the nuclear energy industry, regulatory and government affairs, non-proliferation and diplomacy. It leverages those broad and integrated capabilities by offering consulting and strategic advisory services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure. | |||
 | |||
 | |||
Company: | Threshold Pharmaceuticals, Inc. | ||
Ticker Symbol & Exchange: | THLD (NASDAQ) | ||
Investor Relations Contact: | Denise Powell | ||
Investor Relations Contact Phone: | 650 474 8206 | ||
Web: | www.thresholdpharm.com | ||
Date of Presentation: | to be determined | ||
 | |||
Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, the Company is building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs. | |||
 | |||
TH-302 is a novel drug candidate that is activated under the metabolic conditions typical of cancer cells. The Company has three Phase 1 clinical trials ongoing that are focused on treating solid tumors. | |||
 | |||
 | |||
Company: | ThromboVision, Inc. | ||
Investor Relations Contact: | Sally I Evans, APR | ||
Investor Relations Contact Phone: | office: 713-660-7990, mobile: 713-557-2461 | ||
Web: | www.thrombovision.com | ||
Date of Presentation: | 9/9/09, 3:15 pm, Henry Salon, 5thfl | ||
 | |||
ThromboVision, Inc., a biomedical company committed to helping people lead longer, healthier lives, seeks to provide easy-to-use, rapid-response, cost-effective, and versatile point-of-care clinical discoveries that advance medical diagnosis. The company’s products -- not yet released to market -- will improve medical care by helping physicians diagnose and manage critical cardiovascular risk factors, especially those related to platelet function and antiplatelet drug therapy. ThromboVision has filed a 510(k) application with the FDA for the ThromboGuide® (T-Guide®) platelet aggregation system. This capital efficient company is seeking additional Series B funding to ramp up its market rollout, expected in early 2010. www.thrombovision.com | |||
 | |||
 | |||
Company: | Tianyin Pharmaceutical Co., Inc. | ||
Ticker Symbol & Exchange: | TPI AMEX | ||
Investor Relations Contact: | HC International, Inc. | ||
Investor Relations Contact Phone: | Matt Hayden, 760-452-2047 | ||
Web: | www.tianyinpharma.com | ||
Date of Presentation: | Friday, September 11 at 10:50am | ||
 | |||
Based in Chengdu, China, Tianyin Pharmaceutical Co., Inc. is a primary manufacturer, marketer and supplier of modernized Traditional Chinese Medicine (TCM). Established in 1994, the Company develops and manufactures a diversified portfolio consisting of 33 branded, cost-competitive modernized Traditional Chinese Medicines (TCMs) and 5 generic western medicines addressing a number of indications through its two GMP-certified manufacturing facilities and sells its products through an extensive nationwide distribution network managed by over 720 salespeople. Tianyin possesses a strong R&D platform supported by partnerships with leading Chinese academic institutions and has produced an extensive pipeline of 40 products including several generic western medicines in various stages of the approval process. | |||
 | |||
 | |||
Company: | Tompkins Financial Corporation | ||
Ticker Symbol & Exchange: | NYSE Amex - "TMP" | ||
Investor Relations Contact: | Frank Fetsko, CFO | ||
Investor Relations Contact Phone: | (607) 273-3210 | ||
Web: | www.tompkinsfinancial.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
Tompkins Financial operates 45 banking offices in the NYS markets served by the Company’s subsidiary banks—Tompkins Trust Company, The Bank of Castile, and Mahopac National Bank. Through its community banking subsidiaries, the Company provides traditional banking services, and offers a full range of money management services through Tompkins Investment Services (a division of Tompkins Trust Company). The Company offers insurance services through its Tompkins Insurance Agencies, Inc. subsidiary, an independent agency serving individuals and business clients throughout western New York. The Company also offers fee-based financial planning and wealth management services through its AM&M Financial Services, Inc. subsidiary. | |||
 | |||
 | |||
Company: | TOP SHIPS INC. | ||
Ticker Symbol & Exchange: | NASDAQ:TOPS | ||
Investor Relations Contact: | Michael Mason | ||
Investor Relations Contact Phone: | 212.691.8087 | ||
Web: | www.topships.org | ||
Date of Presentation: | 09/10/09 | ||
 | |||
TOP SHIPS Inc is a leading provider in the worldwide transportation of liquid and petroleum cargoes as well as dry bulk cargoes through the operation of a fleet of twelve tankers and five dry bulk carriers. | |||
 | |||
The Company has established a reputation in the international shipping industry for operating and maintaining its fleet with high standards of performance, reliability and safety. TOPS places a strong emphasis on its high quality double-hull tankers and dry bulk carriers which are largely sister ships, its multi-sector presence, an experienced management team with strong customer relationships, and a reliable track record. | |||
 | |||
TOPS’ fleet consists of eight Handymax double hull tankers used to transport chemical/ petroleum products or crude oil, and five dry bulk carriers with a total cargo capacity of approximately 1 million DWT. | |||
 | |||
 | |||
Company: | TransAtlantic Petroleum Corp. | ||
Ticker Symbol & Exchange: | TSX: CA | ||
Investor Relations Contact: | Kevin Flick | ||
Investor Relations Contact Phone: | 214-265-4794 | ||
Web: | http://www.transatlanticpetroleum.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
TransAtlantic Petroleum Corp. (TSX: TNP) (OTCBB: TAPFF) is a vertically integrated, international energy company engaged in the acquisition, development, exploration, and production of crude oil and natural gas. The Company holds interests in developed and undeveloped properties in Morocco, Turkey, Romania, and California. The Company owns 7 drilling rigs and service equipment. | |||
 | |||
In 2008 and 2009, Mr. Mitchell & Associates (“Mitchell Groupâ€) invested over CDN $175mm in TransAtlantic for a 60% stake. | |||
 | |||
From ’85-’06, Mr. Mitchell built Riata Energy, which was later renamed to SandRidge Energy (NYSE: SD), into one of the largest privately-held energy companies in the United States. Mitchell Group aims to create equal success internationally, with TransAtlantic serving as the investment vehicle. | |||
 | |||
 | |||
Company: | UniPixel, Inc. | ||
Ticker Symbol & Exchange: | OTC BB:UNXL | ||
Investor Relations Contact: | Laura Guerrant-Oiye | ||
Investor Relations Contact Phone: | [email protected], (808) 882-1467 | ||
Web: | www.uni-pixel.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
UniPixel has developed, patented and is commercializing Time-Multiplexed-Optical-Shutter (TMOS), a new color-display technology offering significant advantages over existing display alternatives including lower production cost, lower power consumption, superior brightness, and improved picture quality. UniPixel also produces Opcuity™ Performance Engineered Films which were developed principally for TMOS. UniPixel’s first commerical product will be Opcuity FPR, a fingerprint-resistant protective cover film for touchscreen displays. UniPixel intends to license TMOS to LCD manufacturing partners and will supply Opcuity thin films to those manufacturers. UniPixel recently signed a development agreement for TMOS with Samsung and a distribution agreement for Opcuity FPR with Targus, Inc. | |||
 | |||
 | |||
Company: | US Gold Corporation | ||
Ticker Symbol & Exchange: | NYSE: UXG & TSE: UXG | ||
Investor Relations Contact: | Ian Ball | ||
Investor Relations Contact Phone: | 1 866 441 0690 | ||
Web: | www.usgold.com | ||
Date of Presentation: | September 9th, 2009 | ||
 | |||
US Gold Corporation is a Colorado incorporated gold and silver exploration company. It has a strong treasury, no debt and significant land holdings in Nevada next to Barrick's large Cortez Hills deposit along with a high grade silver/gold discovery in north-western Mexico. US Gold's shares trade on the NYSE Amex and Toronto Stock Exchanges under the symbol UXG. | |||
 | |||
 | |||
Company: | VERO ENERGY INC | ||
Ticker Symbol & Exchange: | TSX:VRO | ||
Investor Relations Contact: | SCOTT KOYICH | ||
Investor Relations Contact Phone: | 403-215-5979 | ||
Web: | WWW.VEROENERGY.CA | ||
Date of Presentation: | THURSDAY, SEPTEMBER 10, 2009 | ||
 | |||
Vero Energy Inc. is a Calgary based, growth oriented company engaged in the exploration, development and production of natural gas, natural gas liquids and oil in Western Canada. Since its inception in November of 2005, Vero has achieved significant growth in: production and production per share; cash flow and cash flow per share; reserves and reserves per share. Vero is committed to growing mainly through the drill bit, but also explores prudent acquisition opportunities that are a strategic fit. Vero has a solid land base of over 150,000 net undeveloped acres and over 245 drilling locations. | |||
 | |||
 | |||
Company: | Victoria Gold | ||
Ticker Symbol & Exchange: | VIT- TSXV | ||
Investor Relations Contact: | Norm Chang | ||
Investor Relations Contact Phone: | 416 866 8800 x 226 | ||
Web: | www.vitgoldcorp.com | ||
Date of Presentation: | September 10th | ||
 | |||
Victoria Gold Corp is focused on value growth per share through efficient exploration and accretive acquisition. Through its Gateway Gold and Stratagold acquisitions, Victoria’s NI 43-101 gold resources now total 4.4 million ounces. In addition, Victoria has a pipeline of exploration projects in Nevada. | |||
 | |||
Victoria’s diversified project portfolio of high-quality projects in prolific mining districts has attracted a large institutional following including Kinross Gold Corporation, who owns ~21% of Victoria’s common shares. | |||
 | |||
In 2009, Victoria is focusing on expeditiously advancing the Eagle Gold Project in the Yukon and the Cove Project in Nevada towards production in a cost-effective manner. | |||
 | |||
 | |||
Company: | Wafergen Bio-systems, Inc. | ||
Ticker Symbol & Exchange: | WGBS.OB | ||
Investor Relations Contact: | Cole Eckhardt | ||
Investor Relations Contact Phone: | (914) 588-6229 | ||
Web: | www.wafergen.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genetic analysis for the life science and pharmaceutical industries. The company is actively developing its SmartChipâ„¢ product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time PCR platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. | |||
 | |||
 | |||
Company: | WellGen, Inc. | ||
Investor Relations Contact: | Bob Hellauer, CFO | ||
Investor Relations Contact Phone: | 732-565-3890 | ||
Web: | www.wellgen.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
WellGen is a life science company at the crossroads of foods and pharmaceuticals. WellGen deploys in-house expertise in nutrigenomics and natural product chemistry to discover and develop proprietary nutraceutical products addressing opportunities in the medical food, functional food, and dietary supplement markets. With our proprietary Alignomxâ„¢ model, WellGen uses data derived at the level of gene expression to determine optimal therapeutic niches for our pipeline of proprietary nutraceuticals. Over the next three years the Companywill transition into a revenue and profit producing entity with commercial activities in three distinct multi-billion dollar growth markets. | |||
 | |||
 | |||
Company: | WesBanco, Inc. | ||
Ticker Symbol & Exchange: | WSBC - NASDAQ Global | ||
Investor Relations Contact: | Robert H. Young | ||
Investor Relations Contact Phone: | (304) 234-9447 | ||
Web: | www.wesbanco.com | ||
Date of Presentation: | 09/09/09 | ||
 | |||
WesBanco, Inc., headquartered in Wheeling, West Virginia, is a multi-state bank holding company with total assets of $5.7 billion. WesBanco's unit banking subsidiary, WesBanco Bank, Inc., currently operates 114 banking offices and 144 ATMs in West Virginia, Ohio and Pennsylvania. WesBanco also operates an insurance brokerage company, WesBanco Insurance Services, Inc., and a full-service broker-dealer, WesBanco Securities, Inc. | |||
 | |||
 | |||
Company: | Western Copper Corporation | ||
Ticker Symbol & Exchange: | TSX: WRN | ||
Investor Relations Contact: | Chiara Orrigoni | ||
Investor Relations Contact Phone: | 1 604 638 2496 | ||
Web: | www westerncoppercorp.com | ||
Date of Presentation: | Wednesday, September 9, 2009 @ 4:30 | ||
 | |||
Western Copper is a Vancouver based exploration and development company with significant gold, copper and molybdenum resources and reserves. | |||
 | |||
Its key asset is the Casino property in the Yukon, which contains 8 million ounces of gold, 4.4 billion pounds of copper and 475 million pounds of copper in reserves. | |||
 | |||
Its Carmacks project, which will produce 32 million pounds per year cathode copper, is scheduled to begin construction in early 2010, and it has two other copper development projects in the pipeline – Hushamu and Redstone. | |||
 | |||
Western Copper has no debt and approximately C$ 15M in cash (Pro-forma data, June 30, 2009). | |||
 | |||
 | |||
Company: | Western Lithium Canada Corporation | ||
Ticker Symbol & Exchange: | TSX-V: WLC | ||
Investor Relations Contact: | Cindy Burnett | ||
Investor Relations Contact Phone: | 604 639 2163 | ||
Web: | www.westernlithium.com | ||
Date of Presentation: | Sept. 11/09 | ||
 | |||
Western Lithium is developing its Nevada lithium deposit to support the new generation of hybrid/electric vehicles. With one of the world’s largest known deposits of lithium, the company is ideally positioned to enter the market as a major supplier of high quality lithium carbonate. | |||
 | |||
The property has a NI 43-101 resource estimate for the initial stage of development and in total hosts a historically estimated 11 million tonnes of lithium carbonate equivalent (LCE). The company intends to produce approximately 25,000 tonnes of LCE annually starting in 2013, coinciding with the expected rise in production of lithium-ion batteries for hybrid/electric vehicles. | |||
 | |||
 | |||
Company: | Wits Gold Limited | ||
Ticker Symbol & Exchange: | WGR-TSX; WIWTY-OTC | ||
Investor Relations Contact: | Mr Hethen Hira | ||
Investor Relations Contact Phone: | 27 11 832 1749 | ||
Web: | www.witsgold.com | ||
Date of Presentation: | September 10 at 8:45AM | ||
 | |||
Wits Gold is an active gold and uranium exploration company with advanced projects adjacent to operating mines in the Witwatersrand Basin, South Africa. The Company has title to NI 43-101 compliant resources of 152 Moz Au, the fifth largest gold resource in the world, in addition to 105 Mlbs of uranium. Current attention is focused on progressing towards a development decision at the adjacent multi-million ounce Bloemhoek and De Bron projects in the southern Free State goldfield. Wits Gold has sufficient funds to finance its current exploration programme for the next 3 to 5 years at currently planned expenditure rates. | |||
 | |||
 | |||
Company: | WSP Holdings | ||
Ticker Symbol & Exchange: | WH: NYSE | ||
Investor Relations Contact: | Crocker Coulson | ||
Investor Relations Contact Phone: | 646-213-1915 | ||
Web: | www.wsphl.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
WSP Holdings Limited develops and manufactures Oil Country Tubular Goods (OCTG) consisting of seamless casing, tubing, drill pipe and connectors and other products used for on-shore and off-shore oil and natural gas exploration, drilling and extraction. The Company manufactures over 400 different products, including those that meet American Petroleum Institute (API) standards and customized, high quality non-API products used in diverse and extreme conditions. The Company is one of top three OCTG suppliers in China and the second largest supplier of China National Petroleum Corporation and one of two China based, non-API suppliers to SINOPEC. Outside of China, WSP Holdings’ customer base spans the world, including North and South America, Russia, Central and Southeast Asia, the Middle East and Africa. | |||
 | |||
 | |||
Company: | Xcellerex, Inc. | ||
Investor Relations Contact: | Jonathan Lieber | ||
Investor Relations Contact Phone: | (508) 480-9235 | ||
Web: | http://www.xcellerex.com | ||
Date of Presentation: | 09/11/09 | ||
 | |||
Xcellerex is revolutionizing the way biomolecules are developed, manufactured and commercialized. The company’s unique, single-use, technology transforms biomanufacturing economics, improving the ability of Xcellerex and its partners to rapidly and cost-effectively deploy manufacturing capacity. For example, fully-integrated manufacturing capacity employing the Company’s technology can be established within one year vs. three to five years at a capital reduction of 50% to 75% as compared to traditional facilities. The technology serves as the foundation for the Company’s three businesses: Single-use Bioreactors and Mixers including the FlexFactory®, Process Development and GMP Manufacturing Services and Proprietary Biomolecules. The Company generated revenues of approximately $13 million in 2008 and anticipates $25 million in 2009. | |||
 | |||
 | |||
Company: | Yongye International, Inc. | ||
Ticker Symbol & Exchange: | YONG Nasdaq GM | ||
Investor Relations Contact: | Larry Gilmore | ||
Investor Relations Contact Phone: | 86-10-8232-8866 x 8880 | ||
Web: | www.yongyeintl.com | ||
Date of Presentation: | September 10 th 4:30pm ET | ||
 | |||
Yongye International, Inc., headquartered in Beijing, is engaged in the development, manufacturing, distribution and sales of fulvic acid based nutrients for plants and animals. Through our long term research and development efforts, Yongye has developed proprietary extraction techniques and patented mixture processes for our plant and animal nutrient products which sell under the brand name of "Shengmingsu". The Company's proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People's Republic of China. The Company sells its products through distributors in ten provinces throughout China. | |||
 | |||
 | |||
Company: | Yuhe International, Inc. | ||
Ticker Symbol & Exchange: | OTCBB: YUII | ||
Investor Relations Contact: | Mr. Jason Wang | ||
Investor Relations Contact Phone: | (765) 409-1844 | ||
Web: | www.yuhepoultry.com | ||
Date of Presentation: | September 10th, 2009 | ||
 | |||
Founded in 1996, Yuhe is the second largest day-old broiler breeder in China. The Company’s main operations involve breeding, as all broilers are sold within a day of hatching. With headquarters in Weifang, Shandong province, the Company has modern facilities and is led by an experienced team which includes experts in chicken breeding, disease prevention and animal husbandry science. Currently, 85% of the Company’s sales are in Shandong province with a customer base of 27 local agents. The Company has imported state-of-the-art equipment from the United States, Germany and Japan and has passed ISO9001 certification, allowing it to adhere to international standards of operations. | |||
 | |||
 | |||
Company: | ZIOPHARM Oncology, Inc. | ||
Ticker Symbol & Exchange: | ZIOP | ||
Investor Relations Contact: | Tyler Cook | ||
Investor Relations Contact Phone: | 617-259-1982 | ||
Web: | www.ziopharm.com | ||
Date of Presentation: | 09/10/09 | ||
 | |||
ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse, portfolio of cancer drugs. Our principal focus is on the development of proprietary small molecule drug candidates that work on validated targets. The goal is to develop intravenous (“IVâ€) and/or oral forms of administration. We believe this strategy will result in lower-risk and lower-cost development programs with product candidates having a low cost of manufacturing to address changing reimbursement requirements around the world. |
About Business Wire
Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.
Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.
Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 30 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.
Business Wire
Global Event Services
310-820-9473
http://www.businesswire.com
http://www.tradeshownews.com
twitter: @tradeshownews
Source: Business Wire Global Event Services
D.C. Insurance Commissioner Abruptly Steps Down
India Proposes Scrapping Commission Loads on Insurance Products
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News